vignette,question_1,question_2,question_3,question_4,question_5,answer_1,answer_2,answer_3,answer_4,answer_5,marks_1,marks_2,marks_3,marks_4,marks_5,Total_Marks_Achieved
" History of Present Illness
A 58-year-old male presents with a 3-week history of gradually worsening fatigue, weight loss, and fever. Over the past week, he has developed pain and redness in his right hand, which has been intermittently swollen. He denies trauma or any recent infections. He also reports having had bilateral leg pain that worsens with activity but improves with rest. The patient has no history of similar symptoms. He has not been on any new medications, and he denies smoking or alcohol use. His family history is notable for autoimmune diseases, as his father has rheumatoid arthritis. 

  Past Medical History
The patient has a history of hypertension for 10 years, managed with an ACE inhibitor. He has no known history of autoimmune diseases or vasculitis. He underwent a cholecystectomy 5 years ago . 

  Physical Examination
VITALS: BP 135/85 mmHg, pulse 88 bpm, temperature 100.4°F. 
GEN: Ill-appearing, mildly febrile, visibly fatigued. 
CARDIAC: Regular rhythm, no murmurs, Feeble peripheral pulses 
PULM: Clear to auscultation bilaterally. 
ABD: Soft, non-tender, no hepatosplenomegaly. 
MSK: Swelling and erythema of the right hand with tenderness to palpation at the metacarpophalangeal joint. Bilateral calf tenderness with no signs of deep venous thrombosis. 
EXT: No edema, but marked tenderness in the lower extremities. 
SKIN: Petechial rash over the anterior shin. 

  Laboratory Results
WBC: 12 x 103 cells/μL (elevated). Hemoglobin: 11.8 g/dL. ESR: 65 mm/h (elevated). Positive anti-ds DNA antibodies. CRP: 45 mg/L (elevated). Urinalysis: 2+ protein, no blood. Creatinine: 1.2 mg/dL.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Systemic Lupus Erythematosus (SLE)**: The patient's symptoms, such as fatigue, weight loss, fever, joint pain, and skin rash, are consistent with SLE. The presence of anti-dsDNA antibodies, which are specific for SLE, further supports this diagnosis. Additionally, the patient's family history of autoimmune diseases, including rheumatoid arthritis, may also suggest a genetic predisposition to autoimmune disorders.

2. **Rheumatoid Arthritis (RA)**: The patient's symptoms, such as joint pain and swelling, particularly in the hands, are consistent with RA. The presence of elevated ESR and CRP levels also suggests an inflammatory process. However, the presence of anti-dsDNA antibodies and the patient's family history of autoimmune diseases may suggest a more complex autoimmune disorder, such as SLE.

3. **Polyarteritis Nodosa (PAN)**: The patient's symptoms, such as fever, fatigue, and joint pain, are consistent with PAN. The presence of petechial rash and calf tenderness may also suggest vasculitis. However, the patient's laboratory results, including the presence of anti-dsDNA antibodies, may suggest a more complex autoimmune disorder, such as SLE.

It is essential to note that these diagnoses are not mutually exclusive, and the patient may have a combination of these conditions. Further testing and evaluation are necessary to determine the underlying cause of the patient's symptoms.","Here are the findings and risk factors that support each possible diagnosis:

**Systemic Lupus Erythematosus (SLE)**

1. **Anti-dsDNA antibodies**: The presence of anti-dsDNA antibodies is a specific marker for SLE and is found in approximately 70% of patients with SLE.
2. **Positive family history**: The patient's family history of autoimmune diseases, including rheumatoid arthritis, may suggest a genetic predisposition to autoimmune disorders.
3. **Skin rash**: The presence of a petechial rash on the anterior shin is consistent with SLE.
4. **Kidney involvement**: The presence of 2+ proteinuria on urinalysis suggests kidney involvement, which is a common feature of SLE.
5. **Elevated ESR and CRP**: The elevated ESR and CRP levels suggest an inflammatory process, which is consistent with SLE.

**Rheumatoid Arthritis (RA)**

1. **Joint pain and swelling**: The patient's symptoms, such as joint pain and swelling, particularly in the hands, are consistent with RA.
2. **Elevated ESR and CRP**: The elevated ESR and CRP levels suggest an inflammatory process, which is consistent with RA.
3. **Positive family history**: The patient's family history of autoimmune diseases, including rheumatoid arthritis, may suggest a genetic predisposition to autoimmune disorders.
4. **Swollen and erythematous hand**: The presence of a swollen and erythematous hand is consistent with RA.

**Polyarteritis Nodosa (PAN)**

1. **Petechial rash**: The presence of a petechial rash on the anterior shin is consistent with PAN.
2. **Calf tenderness**: The patient's calf tenderness may suggest vasculitis, which is a common feature of PAN.
3. **Elevated ESR and CRP**: The elevated ESR and CRP levels suggest an inflammatory process, which is consistent with PAN.
4. **Kidney involvement**: The presence of 2+ proteinuria on urinalysis suggests kidney involvement, which is a common feature of PAN.

However, the presence of anti-dsDNA antibodies and the patient's family history of autoimmune diseases may suggest a more complex autoimmune disorder, such as SLE, rather than PAN.","Here are the findings that oppose each possible diagnosis:

**Systemic Lupus Erythematosus (SLE)**

1. **Lack of mucocutaneous involvement**: SLE often presents with mucocutaneous involvement, such as oral ulcers, skin lesions, or alopecia. The patient's lack of these symptoms makes SLE less likely.
2. **No neurological symptoms**: SLE can present with neurological symptoms, such as seizures or psychosis. The patient's lack of these symptoms makes SLE less likely.
3. **Normal complement levels**: SLE is often associated with low complement levels. The patient's complement levels are not mentioned, but if they are normal, it would make SLE less likely.
4. **No specific anti-SLE antibodies**: While anti-dsDNA antibodies are specific for SLE, other antibodies, such as anti-Sm or anti-RNP, are also commonly found in SLE patients. The patient's lack of these antibodies would make SLE less likely.

**Rheumatoid Arthritis (RA)**

1. **Lack of symmetric joint involvement**: RA typically presents with symmetric joint involvement, particularly in the hands and feet. The patient's unilateral joint involvement makes RA less likely.
2. **No morning stiffness**: RA patients often experience morning stiffness that lasts for hours. The patient's lack of morning stiffness makes RA less likely.
3. **No rheumatoid factor**: Rheumatoid factor is a common antibody found in RA patients. The patient's lack of rheumatoid factor would make RA less likely.
4. **No radiographic evidence of joint damage**: RA patients often have radiographic evidence of joint damage, such as erosions or joint space narrowing. The patient's lack of radiographic evidence of joint damage makes RA less likely.

**Polyarteritis Nodosa (PAN)**

1. **Lack of systemic symptoms**: PAN often presents with systemic symptoms, such as fever, weight loss, and fatigue. The patient's lack of these symptoms makes PAN less likely.
2. **No renal involvement**: PAN often involves the kidneys, leading to renal failure or hypertension. The patient's lack of renal involvement makes PAN less likely.
3. **No gastrointestinal symptoms**: PAN often involves the gastrointestinal tract, leading to symptoms such as abdominal pain or diarrhea. The patient's lack of gastrointestinal symptoms makes PAN less likely.
4. **No specific vasculitis markers**: PAN is often associated with specific vasculitis markers, such as ANCA or anti-GBM antibodies. The patient's lack of these markers would make PAN less likely.

These findings do not rule out each diagnosis entirely, but they do suggest that each diagnosis is less likely than the others. Further testing and evaluation are necessary to determine the underlying cause of the patient's symptoms.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Systemic Lupus Erythematosus (SLE)**

The patient's symptoms, such as fatigue, weight loss, fever, joint pain, and skin rash, are consistent with SLE. The presence of anti-dsDNA antibodies, which are specific for SLE, further supports this diagnosis. Additionally, the patient's family history of autoimmune diseases, including rheumatoid arthritis, may suggest a genetic predisposition to autoimmune disorders.

While the patient's lack of mucocutaneous involvement and normal complement levels make SLE less likely, the presence of anti-dsDNA antibodies and the patient's overall clinical picture make SLE the most likely diagnosis.

**Supporting evidence:**

* Anti-dsDNA antibodies
* Positive family history of autoimmune diseases
* Skin rash
* Kidney involvement (2+ proteinuria)
* Elevated ESR and CRP

**Opposing evidence:**

* Lack of mucocutaneous involvement
* Normal complement levels (not mentioned, but would be expected)

**Differential diagnosis:**

* Rheumatoid Arthritis (RA)
* Polyarteritis Nodosa (PAN)

**Treatment plan:**

* Corticosteroids (e.g., prednisone) to reduce inflammation and suppress the immune system
* Immunosuppressive agents (e.g., hydroxychloroquine) to reduce the risk of flare-ups and prevent organ damage
* Regular monitoring of kidney function and blood counts to adjust treatment as needed
* Education on disease management, including lifestyle modifications and medication adherence

**Follow-up:**

* Schedule regular follow-up appointments to monitor the patient's response to treatment and adjust the treatment plan as needed.
* Consider referring the patient to a rheumatologist or nephrologist for further evaluation and management of the patient's kidney involvement.","Based on the final diagnosis of Systemic Lupus Erythematosus (SLE), the following additional steps should be taken:

**Immediate steps:**

1. **Start corticosteroids**: Begin treatment with corticosteroids, such as prednisone, to reduce inflammation and suppress the immune system.
2. **Monitor kidney function**: Regularly monitor the patient's kidney function, including serum creatinine and urine protein levels, to adjust treatment as needed.
3. **Order additional laboratory tests**: Order additional laboratory tests, such as complete blood count (CBC), liver function tests (LFTs), and antiphospholipid antibodies (aPL), to assess the patient's overall health and identify any potential complications.
4. **Educate the patient**: Educate the patient on the disease, its symptoms, and the treatment plan, including the importance of medication adherence and lifestyle modifications.

**Short-term steps (within 1-2 weeks):**

1. **Immunosuppressive therapy**: Consider starting immunosuppressive therapy, such as hydroxychloroquine, to reduce the risk of flare-ups and prevent organ damage.
2. **Monitor for side effects**: Regularly monitor the patient for side effects of corticosteroids and immunosuppressive therapy, such as weight gain, mood changes, and increased risk of infections.
3. **Adjust treatment as needed**: Adjust the treatment plan as needed based on the patient's response to therapy and any changes in their symptoms or laboratory results.

**Long-term steps (within 1-3 months):**

1. **Regular follow-up appointments**: Schedule regular follow-up appointments to monitor the patient's response to treatment and adjust the treatment plan as needed.
2. **Monitor for organ damage**: Regularly monitor the patient for signs of organ damage, such as kidney disease, cardiovascular disease, and neurological disease.
3. **Consider referral to a specialist**: Consider referring the patient to a rheumatologist or nephrologist for further evaluation and management of the patient's kidney involvement.

**Additional considerations:**

1. **Family planning**: Consider the patient's reproductive plans and discuss the risks and benefits of pregnancy in patients with SLE.
2. **Vaccinations**: Consider vaccinating the patient against influenza and pneumococcal disease to reduce the risk of infections.
3. **Lifestyle modifications**: Encourage the patient to make lifestyle modifications, such as maintaining a healthy weight, exercising regularly, and avoiding smoking, to reduce the risk of complications.

By taking these additional steps, the patient can receive comprehensive care and management for their SLE, reducing the risk of complications and improving their quality of life.","{""Score"":3,""Rationale"":""The answer includes Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Polyarteritis Nodosa (a type of vasculitis), matching the three concepts required by the rubric.""}","{
  ""Score"": 4,
  ""Rationale"": ""The answer correctly includes the key SLE features (anti-dsDNA, rash, proteinuria, elevated ESR/CRP, family history) and RA features (hand swelling, elevated ESR/CRP, family history). However, it does not mention the vasculitis criteria of fever and weight loss, and it omits any reference to peripheral vascular disease. Therefore, 2 points each for SLE and RA are awarded, but no points for vasculitis or peripheral vascular disease.""
}","{""Score"":2,""Rationale"":""The answer only includes a concept that matches the rubric (absence of morning stiffness for rheumatoid arthritis). No mention of the specific SLE criteria (renal involvement or butterfly rash), vasculitis criteria (vessel involvement, aneurysms, pANCA), or peripheral vascular disease (palpable pulses) from the rubric, so no points for those sections.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Systemic Lupus Erythematosus (SLE) and lists the key clinical findings (fever, weight loss, elevated ESR/CRP, rash, proteinuria) that match the high‑scoring example, thus earning full credit.""}","{""Score"":2,""Rationale"":""Referral to a rheumatologist is included (2 points). No mention of kidney biopsy, and hydroxychloroquine is noted without the required rheumatologist guidance, so those items receive no points.""}",13.0
"History of Present Illness 
A 58-year-old male presents with a 6-month history of progressive fatigue, weight loss, and peripheral edema. He also reports shortness of breath on exertion and difficulty swallowing solid foods for the past 2 months. His urine has become frothy, and he has noticed some tingling sensations in his hands. He denies chest pain, fever, or night sweats. There is no history of hypertension, diabetes, or known heart disease. 
Past Medical History 
The patient has a 10-year history of rheumatoid arthritis, well-controlled with methotrexate. He denies smoking or alcohol use. Family history is negative for any genetic disorders. 
Physical Examination 
VITALS: BP 110/70 mmHg, pulse 90/min, temperature 98.4°F. 
GEN: Thin, pale, fatigued. 
CARDIAC: No murmurs, but there is a slight periorbital edema. 
PULM: Clear to auscultation bilaterally. 
ABD: Mild hepatomegaly (2 cm below the costal margin), no tenderness. 
EXT: Bilateral pedal edema, no erythema or ulcers. 
NEURO: Decreased sensation to light touch in both feet, absent ankle reflexes. 

Laboratory Results
Urinalysis shows 2+ proteinuria, and serum creatinine is 1.5 mg/dL. The BNP is elevated at 550 pg/mL. Serum free light chains are elevated, and a biopsy of abdominal fat reveals amyloid deposits. Echocardiogram shows concentric left ventricular hypertrophy with normal systolic function. Hemoglobin levels within normal range.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Amyloid Light-Chain (AL) Amyloidosis**: This is a type of amyloidosis caused by the deposition of light-chain proteins produced by plasma cells. The patient's history of rheumatoid arthritis, elevated serum free light chains, and biopsy findings of amyloid deposits in the abdominal fat are consistent with this diagnosis. The presence of proteinuria, nephrotic syndrome, and congestive heart failure symptoms also support this diagnosis.

2. **Cardiac Amyloidosis**: This is a condition characterized by the deposition of amyloid fibrils in the heart, leading to restrictive cardiomyopathy. The patient's symptoms of shortness of breath, fatigue, and peripheral edema, along with the echocardiogram findings of concentric left ventricular hypertrophy, are consistent with this diagnosis. The elevated BNP level also supports this diagnosis.

3. **Nephrotic Syndrome due to Amyloidosis**: This is a condition characterized by the deposition of amyloid fibrils in the kidneys, leading to proteinuria and nephrotic syndrome. The patient's symptoms of peripheral edema, proteinuria, and elevated serum creatinine level are consistent with this diagnosis. The biopsy findings of amyloid deposits in the abdominal fat also support this diagnosis.

These three diagnoses are not mutually exclusive, and the patient may have a combination of these conditions. Further testing, such as a bone marrow biopsy and imaging studies, may be necessary to confirm the diagnosis and guide treatment.","Here are the findings and risk factors that support each possible diagnosis:

**Amyloid Light-Chain (AL) Amyloidosis**

1. **History of Rheumatoid Arthritis**: The patient has a 10-year history of rheumatoid arthritis, which is a known risk factor for developing AL amyloidosis. Rheumatoid arthritis can lead to the production of abnormal plasma cells that produce light-chain proteins, which can deposit in various tissues, including the kidneys and heart.
2. **Elevated Serum Free Light Chains**: The patient's serum free light chains are elevated, which is a hallmark of AL amyloidosis. This suggests that the patient's plasma cells are producing abnormal light-chain proteins that are being deposited in tissues.
3. **Biopsy Findings of Amyloid Deposits**: The biopsy of abdominal fat reveals amyloid deposits, which is a definitive finding of AL amyloidosis.
4. **Proteinuria and Nephrotic Syndrome**: The patient's proteinuria and nephrotic syndrome are consistent with AL amyloidosis, which can cause kidney damage and lead to proteinuria.
5. **Family History of Plasma Cell Dyscrasias**: Although the patient denies a family history of genetic disorders, AL amyloidosis can be associated with a family history of plasma cell dyscrasias, such as multiple myeloma.

**Cardiac Amyloidosis**

1. **Echocardiogram Findings**: The echocardiogram shows concentric left ventricular hypertrophy with normal systolic function, which is a characteristic finding of cardiac amyloidosis.
2. **Elevated BNP Level**: The patient's elevated BNP level is consistent with cardiac amyloidosis, which can cause heart failure and lead to elevated BNP levels.
3. **Shortness of Breath and Fatigue**: The patient's symptoms of shortness of breath and fatigue are consistent with cardiac amyloidosis, which can cause heart failure and lead to these symptoms.
4. **Peripheral Edema**: The patient's peripheral edema is consistent with cardiac amyloidosis, which can cause fluid retention and lead to peripheral edema.
5. **Absence of Hypertension**: The patient's absence of hypertension is consistent with cardiac amyloidosis, which can cause heart failure and lead to elevated blood pressure.

**Nephrotic Syndrome due to Amyloidosis**

1. **Proteinuria and Nephrotic Syndrome**: The patient's proteinuria and nephrotic syndrome are consistent with amyloidosis, which can cause kidney damage and lead to proteinuria.
2. **Elevated Serum Creatinine Level**: The patient's elevated serum creatinine level is consistent with amyloidosis, which can cause kidney damage and lead to elevated serum creatinine levels.
3. **Biopsy Findings of Amyloid Deposits**: The biopsy of abdominal fat reveals amyloid deposits, which is a definitive finding of amyloidosis.
4. **Family History of Plasma Cell Dyscrasias**: Although the patient denies a family history of genetic disorders, amyloidosis can be associated with a family history of plasma cell dyscrasias, such as multiple myeloma.
5. **Absence of Hypertension**: The patient's absence of hypertension is consistent with amyloidosis, which can cause kidney damage and lead to elevated blood pressure.

These findings and risk factors support each possible diagnosis and suggest that the patient may have a combination of these conditions. Further testing, such as a bone marrow biopsy and imaging studies, may be necessary to confirm the diagnosis and guide treatment.","Here are the findings that oppose each possible diagnosis or were expected but not present:

**Amyloid Light-Chain (AL) Amyloidosis**

1. **Expected but not present: Elevated Hemoglobin Level**: AL amyloidosis is often associated with anemia, but the patient's hemoglobin level is within normal range.
2. **Expected but not present: Bone Marrow Plasmacytosis**: AL amyloidosis is often associated with bone marrow plasmacytosis, but the patient's bone marrow biopsy is not mentioned.
3. **Expected but not present: Elevated Serum Calcium Level**: AL amyloidosis can cause hypercalcemia due to bone destruction, but the patient's serum calcium level is not mentioned.
4. **Opposing finding: Normal Echocardiogram**: AL amyloidosis can cause cardiac involvement, but the patient's echocardiogram shows normal systolic function.
5. **Opposing finding: Absence of Kidney Failure**: AL amyloidosis can cause kidney failure, but the patient's serum creatinine level is only mildly elevated.

**Cardiac Amyloidosis**

1. **Expected but not present: Hypertension**: Cardiac amyloidosis can cause hypertension due to heart failure, but the patient's blood pressure is normal.
2. **Expected but not present: Elevated Troponin Level**: Cardiac amyloidosis can cause cardiac damage, but the patient's troponin level is not mentioned.
3. **Expected but not present: ECG Changes**: Cardiac amyloidosis can cause ECG changes, such as low voltage QRS complexes, but the patient's ECG is not mentioned.
4. **Opposing finding: Normal Serum Creatinine Level**: Cardiac amyloidosis can cause kidney failure, but the patient's serum creatinine level is only mildly elevated.
5. **Opposing finding: Absence of Peripheral Edema**: Cardiac amyloidosis can cause fluid retention and peripheral edema, but the patient's peripheral edema is mild.

**Nephrotic Syndrome due to Amyloidosis**

1. **Expected but not present: Hypertension**: Amyloidosis can cause hypertension due to kidney damage, but the patient's blood pressure is normal.
2. **Expected but not present: Elevated Serum Creatinine Level**: Amyloidosis can cause kidney failure, but the patient's serum creatinine level is only mildly elevated.
3. **Expected but not present: Proteinuria > 3.5 g/24 hours**: Amyloidosis can cause nephrotic syndrome, but the patient's proteinuria is only 2+.
4. **Opposing finding: Normal Echocardiogram**: Amyloidosis can cause cardiac involvement, but the patient's echocardiogram shows normal systolic function.
5. **Opposing finding: Absence of Kidney Failure**: Amyloidosis can cause kidney failure, but the patient's serum creatinine level is only mildly elevated.

These findings oppose each possible diagnosis or were expected but not present, suggesting that the patient may not have the expected findings for each diagnosis. Further testing, such as a bone marrow biopsy and imaging studies, may be necessary to confirm the diagnosis and guide treatment.","Based on the patient's symptoms, laboratory results, and physical examination findings, I would make the following final diagnosis:

**Amyloid Light-Chain (AL) Amyloidosis**

The patient's history of rheumatoid arthritis, elevated serum free light chains, and biopsy findings of amyloid deposits in the abdominal fat are consistent with AL amyloidosis. The patient's proteinuria, nephrotic syndrome, and congestive heart failure symptoms also support this diagnosis. The absence of hypertension, elevated troponin level, and ECG changes makes cardiac amyloidosis less likely. The patient's mild kidney dysfunction and absence of kidney failure make nephrotic syndrome due to amyloidosis less likely.

**Supporting evidence:**

* History of rheumatoid arthritis
* Elevated serum free light chains
* Biopsy findings of amyloid deposits in the abdominal fat
* Proteinuria and nephrotic syndrome
* Congestive heart failure symptoms
* Absence of hypertension, elevated troponin level, and ECG changes

**Treatment plan:**

* Referral to a hematologist for further evaluation and management
* Bone marrow biopsy to confirm the diagnosis and assess for plasma cell dyscrasias
* Imaging studies (e.g., PET scan, MRI) to assess for cardiac and renal involvement
* Treatment with melphalan and dexamethasone to reduce plasma cell proliferation and prevent further amyloid deposition
* Monitoring of kidney function and cardiac status to assess for disease progression

**Prognosis:**

* The prognosis for AL amyloidosis is generally poor, with a median survival of 2-5 years.
* The patient's age, comorbidities, and disease severity will impact their prognosis.
* Early diagnosis and treatment may improve outcomes and prolong survival.

**Follow-up:**

* Regular monitoring of kidney function and cardiac status
* Imaging studies to assess for disease progression
* Adjustments to treatment plan as needed to optimize outcomes.","Based on the final diagnosis of Amyloid Light-Chain (AL) Amyloidosis, the following additional steps should be taken:

**Step 1: Bone Marrow Biopsy**

* Schedule a bone marrow biopsy to confirm the diagnosis and assess for plasma cell dyscrasias.
* This will help to identify the underlying cause of the patient's amyloidosis and guide treatment.

**Step 2: Imaging Studies**

* Schedule imaging studies (e.g., PET scan, MRI) to assess for cardiac and renal involvement.
* This will help to evaluate the extent of disease and guide treatment.

**Step 3: Plasma Cell Count**

* Perform a plasma cell count to assess for plasma cell proliferation.
* This will help to guide treatment and monitor response to therapy.

**Step 4: Serum Free Light Chain (SFLC) Assay**

* Perform a serum free light chain (SFLC) assay to assess for abnormal light chain production.
* This will help to guide treatment and monitor response to therapy.

**Step 5: Treatment with Melphalan and Dexamethasone**

* Initiate treatment with melphalan and dexamethasone to reduce plasma cell proliferation and prevent further amyloid deposition.
* This will help to slow disease progression and improve outcomes.

**Step 6: Monitoring of Kidney Function and Cardiac Status**

* Regularly monitor kidney function and cardiac status to assess for disease progression.
* This will help to adjust treatment plan as needed to optimize outcomes.

**Step 7: Referral to a Hematologist**

* Refer the patient to a hematologist for further evaluation and management.
* This will help to ensure that the patient receives comprehensive care and optimal treatment.

**Step 8: Genetic Testing**

* Consider genetic testing to identify any underlying genetic mutations that may be contributing to the patient's amyloidosis.
* This will help to guide treatment and monitor response to therapy.

**Step 9: Supportive Care**

* Provide supportive care to manage symptoms and improve quality of life.
* This may include pain management, nutritional support, and emotional support.

**Step 10: Regular Follow-up**

* Schedule regular follow-up appointments to monitor disease progression and adjust treatment plan as needed.
* This will help to optimize outcomes and improve quality of life.

By taking these additional steps, we can improve the patient's outcomes and quality of life, and provide comprehensive care for their Amyloid Light-Chain (AL) Amyloidosis.","{""Score"":1,""Rationale"":""The answer includes Amyloidosis, which matches a rubric item. The other listed conditions (Cardiac Amyloidosis and Nephrotic Syndrome due to Amyloidosis) do not correspond to Congestive Cardiac Failure, Chronic Kidney Disease, or Multiple Myeloma as specified in the rubric, so no additional points are awarded.""}","{""Score"":2,""Rationale"":""The answer includes the key findings for amyloidosis (elevated free light chains, biopsy amyloid deposits, proteinuria, edema, concentric LVH) matching the rubric, but does not explicitly identify or list the other three diagnoses (Congestive Cardiac Failure, Chronic Kidney Disease, Multiple Myeloma) required for the remaining points.""}","{""Score"":0,""Rationale"":""The answer does not contain any of the specific concepts or opposing findings listed in the high‑scoring example (e.g., no mention of BNP/LVH, proteinuria, serum free light chains, neuropathy, fatigue, weight loss, amyloid biopsy confirmation, or absence of Bence Jones proteins). Therefore, no points are awarded.""}","{""Score"":2,""Rationale"":""Student correctly identified amyloidosis (AL amyloidosis) as the diagnosis, matching the high‑scoring example's key concept of amyloidosis diagnosis based on clinical presentation and biopsy confirmation.""}","{""Score"":2,""Rationale"":""The answer includes a bone marrow biopsy, which matches one of the three required items. It does not explicitly mention a cardiac MRI or a renal biopsy, so only 2 of the 6 possible points are awarded.""}",7.0
"History of Present Illness
A 59-year-old male presents with swelling and pain in his right leg that started 3 days ago. He was discharged from the hospital 2 weeks ago after undergoing knee replacement surgery, during which he received prophylactic low molecular weight heparin. He reports intermittent fever and recent episodes of palpitations. He denies chest pain, shortness of breath, or prior deep vein thrombosis (DVT). 

  Past Medical History
He has a history of osteoarthritis requiring knee replacement. He has hypertension, controlled with amlodipine, and a history of dyslipidemia. He has no history of malignancy or clotting disorders. 

  Physical Examination
VITALS: BP 125/80 mmHg, pulse 102/min, temperature 99.6°F. 
GEN: Appears mildly uncomfortable. 
CARDIAC: Regular rhythm, no murmurs or gallops. 
PULM: Clear to auscultation bilaterally. 
ABD: Soft, non-tender. 
EXT: Right leg swollen with mild erythema and tenderness along the femoral vein. Homans' sign is positive. No ulcers or skin changes. 
SKIN: Petechiae on both forearms. 

  Laboratory Results
Platelet count has decreased to 58 x 10³/μL from 210 x 10³/μL 10 days ago. D-dimer is elevated at 5.2 μg/mL. The Heparin-PF4 antibody test is positive. Ultrasound reveals a thrombus in the right femoral vein.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's presentation and laboratory results, here are three possible diagnoses:

1. **Heparin-Induced Thrombocytopenia (HIT)**: This is a serious complication of heparin therapy, characterized by a decrease in platelet count and the formation of antibodies against the heparin-PF4 complex. The patient's history of recent heparin use, positive heparin-PF4 antibody test, and thrombocytopenia are consistent with HIT.

2. **Deep Vein Thrombosis (DVT) with Thrombocytopenia**: The patient's symptoms of swelling, pain, and erythema in the right leg, along with the ultrasound findings of a thrombus in the right femoral vein, suggest a DVT. The thrombocytopenia could be a secondary effect of the DVT or another underlying condition.

3. **Immune Thrombocytopenia (ITP)**: Although less likely, ITP is a possibility, given the patient's thrombocytopenia and the presence of petechiae on the forearms. However, the patient's recent history of heparin use and the positive heparin-PF4 antibody test make HIT a more likely diagnosis.

It's essential to note that HIT is a medical emergency, and prompt diagnosis and treatment are crucial to prevent further complications.","Here are the findings and risk factors supporting each possible diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

1. **Recent heparin use**: The patient was discharged from the hospital 2 weeks ago after undergoing knee replacement surgery, during which he received prophylactic low molecular weight heparin.
2. **Positive heparin-PF4 antibody test**: This is a specific test for HIT, and a positive result indicates the presence of antibodies against the heparin-PF4 complex.
3. **Thrombocytopenia**: The patient's platelet count has decreased significantly from 210 x 10³/μL to 58 x 10³/μL, which is consistent with HIT.
4. **Thrombosis**: The presence of a thrombus in the right femoral vein suggests that the patient's HIT has led to the formation of a blood clot.
5. **Timing**: The patient's symptoms and laboratory results are consistent with the typical timing of HIT, which usually occurs 5-10 days after the initiation of heparin therapy.

**Deep Vein Thrombosis (DVT) with Thrombocytopenia**

1. **Swelling and pain in the right leg**: These symptoms are consistent with a DVT, and the patient's recent history of knee replacement surgery increases his risk for DVT.
2. **Ultrasound findings**: The ultrasound revealed a thrombus in the right femoral vein, which confirms the presence of a DVT.
3. **Elevated D-dimer**: The patient's D-dimer is elevated, which is a marker of thrombosis.
4. **Risk factors for DVT**: The patient's recent surgery, immobility, and history of cancer (none mentioned, but the patient has osteoarthritis) increase his risk for DVT.

**Immune Thrombocytopenia (ITP)**

1. **Petechiae on the forearms**: These are small, pinpoint bleeding spots that are consistent with ITP.
2. **Thrombocytopenia**: The patient's platelet count is significantly decreased, which is a hallmark of ITP.
3. **Absence of other risk factors**: The patient does not have any other risk factors for ITP, such as recent infection, medication use, or autoimmune disorders.

However, the presence of a positive heparin-PF4 antibody test and the patient's recent history of heparin use make HIT a more likely diagnosis.","Here are the findings opposing each possible diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

1. **Absence of other risk factors**: HIT is more common in patients who have received unfractionated heparin or have a history of HIT. The patient's use of low molecular weight heparin and lack of prior HIT make this diagnosis less likely.
2. **No history of malignancy**: HIT is more common in patients with malignancy, particularly those with a history of cancer. The patient's lack of malignancy history makes this diagnosis less likely.
3. **No other signs of thrombosis**: While the patient has a thrombus in the right femoral vein, there is no evidence of other thromboses, such as pulmonary embolism or arterial thrombosis, which are common in HIT.
4. **No significant elevation in platelet count before thrombocytopenia**: In HIT, the platelet count often increases before decreasing, a phenomenon known as ""platelet rebound."" The patient's platelet count decreased without a preceding increase makes this diagnosis less likely.

**Deep Vein Thrombosis (DVT) with Thrombocytopenia**

1. **No other signs of DVT**: While the patient has a thrombus in the right femoral vein, there is no evidence of other signs of DVT, such as swelling, pain, or erythema in other limbs.
2. **No significant elevation in D-dimer**: While the patient's D-dimer is elevated, it is not significantly elevated, which is often seen in DVT.
3. **No history of recent surgery or trauma**: DVT is more common in patients who have recently undergone surgery or experienced trauma. The patient's recent knee replacement surgery increases his risk for DVT, but the absence of other risk factors makes this diagnosis less likely.
4. **No other risk factors for DVT**: The patient does not have any other risk factors for DVT, such as immobility, cancer, or genetic predisposition.

**Immune Thrombocytopenia (ITP)**

1. **No other signs of ITP**: While the patient has petechiae on the forearms, there is no evidence of other signs of ITP, such as purpura, ecchymoses, or bleeding gums.
2. **No significant elevation in reticulocyte count**: In ITP, the reticulocyte count often increases as the bone marrow tries to compensate for the decreased platelet count. The patient's reticulocyte count is not significantly elevated, which makes this diagnosis less likely.
3. **No history of recent infection or medication use**: ITP is more common in patients who have recently experienced an infection or have been exposed to certain medications. The patient's lack of these risk factors makes this diagnosis less likely.
4. **No other autoimmune disorders**: ITP is often associated with other autoimmune disorders, such as autoimmune hemolytic anemia or rheumatoid arthritis. The patient does not have any other autoimmune disorders, which makes this diagnosis less likely.","Based on the patient's presentation, laboratory results, and the findings supporting and opposing each possible diagnosis, I would make the following final diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

The patient's recent history of heparin use, positive heparin-PF4 antibody test, thrombocytopenia, and thrombosis in the right femoral vein are all consistent with HIT. While there are some findings that oppose this diagnosis, such as the absence of other risk factors and the lack of significant elevation in platelet count before thrombocytopenia, the overall evidence points towards HIT as the most likely diagnosis.

**Reasoning:**

* The patient's recent history of heparin use and positive heparin-PF4 antibody test are strong indicators of HIT.
* The thrombocytopenia and thrombosis in the right femoral vein are consistent with HIT.
* While there are some findings that oppose this diagnosis, they are not sufficient to rule out HIT.
* The patient's symptoms and laboratory results are consistent with the typical timing and presentation of HIT.

**Management:**

* Discontinue heparin and any other anticoagulants.
* Administer alternative anticoagulants, such as argatroban or bivalirudin, to prevent further thrombosis.
* Monitor the patient's platelet count and adjust the anticoagulant therapy as needed.
* Consider performing a repeat heparin-PF4 antibody test to confirm the diagnosis.

**Prognosis:**

* The prognosis for patients with HIT is generally good if treated promptly and appropriately.
* However, HIT can be a life-threatening condition if not recognized and treated promptly.
* The patient's outcome will depend on the severity of the thrombosis and the effectiveness of the anticoagulant therapy.","Based on the final diagnosis of Heparin-Induced Thrombocytopenia (HIT), the following additional steps should be taken:

**Immediate Steps:**

1. **Discontinue heparin and any other anticoagulants**: Immediately discontinue heparin and any other anticoagulants that the patient is receiving.
2. **Administer alternative anticoagulants**: Administer alternative anticoagulants, such as argatroban or bivalirudin, to prevent further thrombosis.
3. **Monitor the patient's platelet count**: Monitor the patient's platelet count closely to ensure that it is increasing and to adjust the anticoagulant therapy as needed.
4. **Perform a repeat heparin-PF4 antibody test**: Consider performing a repeat heparin-PF4 antibody test to confirm the diagnosis and to monitor for the development of antibodies.

**Short-Term Steps:**

1. **Monitor for thrombosis**: Monitor the patient for signs of thrombosis, such as swelling, pain, or erythema in the affected limb.
2. **Monitor for bleeding**: Monitor the patient for signs of bleeding, such as petechiae, ecchymoses, or bleeding gums.
3. **Monitor the patient's renal function**: Monitor the patient's renal function closely, as some anticoagulants, such as argatroban, can affect renal function.
4. **Monitor the patient's liver function**: Monitor the patient's liver function closely, as some anticoagulants, such as bivalirudin, can affect liver function.

**Long-Term Steps:**

1. **Avoid heparin and other anticoagulants**: Avoid using heparin and other anticoagulants in the future, as the patient is at risk for developing HIT again.
2. **Use alternative anticoagulants**: Use alternative anticoagulants, such as argatroban or bivalirudin, in the future if the patient requires anticoagulation therapy.
3. **Monitor for recurrence**: Monitor the patient for signs of recurrence of HIT, such as thrombocytopenia or thrombosis.
4. **Consider genetic testing**: Consider genetic testing to identify genetic predispositions to HIT.

**Patient Education:**

1. **Educate the patient about HIT**: Educate the patient about HIT, its symptoms, and its treatment.
2. **Educate the patient about anticoagulant therapy**: Educate the patient about anticoagulant therapy, its risks, and its benefits.
3. **Educate the patient about monitoring**: Educate the patient about the importance of monitoring their platelet count and renal and liver function.
4. **Educate the patient about recurrence**: Educate the patient about the risk of recurrence of HIT and the importance of monitoring for signs of recurrence.","{""Score"":2,""Rationale"":""The answer includes Heparin-Induced Thrombocytopenia (HIT) and Deep Vein Thrombosis (DVT), which match two of the three rubric items. Fat embolism is not mentioned, so only 2 of 3 points are awarded.""}","{""Score"":4,""Rationale"":""The answer correctly identifies Heparin-Induced Thrombocytopenia and Deep Vein Thrombosis as in the rubric, earning 2 points each. It does not mention Fat Embolism, which is required for the third 2‑point item, so no points are awarded for that component.""}","{""Score"":4,""Rationale"":""The response includes two of the three required diagnoses (Heparin-Induced Thrombocytopenia and Deep Vein Thrombosis), matching those concepts in the high‑scoring example (2 points each). It does not mention Fat Embolism, so no points are awarded for that item. Total score is 4 out of 6.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Heparin-Induced Thrombocytopenia (HIT) and includes the key concepts from the high‑scoring example: recent heparin use, positive Heparin‑PF4 antibody test, thrombocytopenia, and new thrombosis, thus meeting all rubric criteria for full credit.""}","{""Score"":6,""Rationale"":""Student included all three required actions: discontinuation of heparin, initiation of alternative anticoagulation (argatroban), and close platelet count monitoring, matching the rubric.""}",18.0
"History of Present Illness
A 44-year-old female presents with a 6-month history of unintentional weight gain, especially in her abdomen and face. She notes the appearance of purple striae on her abdomen and has recently developed increased acne and facial hair growth. She reports fatigue, insomnia, and mood swings. Over the last month, she has had progressive weakness in her legs, which is most noticeable when climbing stairs.

Past Medical History
The patient has a history of polycystic ovary syndrome (PCOS), for which she has been treated intermittently with oral contraceptives. She denies any history of diabetes or previous steroid use.

Physical Examination
VITALS: BP 170/110 mmHg, pulse 82/min, temperature 98.5°F.
GEN: Overweight, with moon facies and a central distribution of fat.
CARDIAC: Regular rhythm, no murmurs.
PULM: Clear to auscultation bilaterally.
ABD: Obese with prominent abdominal striae and a rounded abdomen.
EXT: Bilateral proximal muscle weakness, especially in the thighs.
SKIN: Purple striae on the abdomen, mild acne on the back and face.

Laboratory Results
Serum cortisol levels are elevated, with a 24-hour urine cortisol excretion of 500 μg/day (normal: <50 μg/day). ACTH is raised, and MRI of the pituitary gland shows a small adenoma.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Cushing's Syndrome**: This is a condition caused by excess cortisol levels in the body, which can be due to various reasons such as a pituitary adenoma (as seen in this patient), adrenal gland tumors, or long-term use of corticosteroid medications. The patient's symptoms, including weight gain, purple striae, acne, facial hair growth, and muscle weakness, are consistent with Cushing's syndrome.

2. **Pituitary Adenoma with Hypercortisolism**: The patient's MRI shows a small adenoma in the pituitary gland, which is secreting excess ACTH (adrenocorticotropic hormone). This leads to increased cortisol production by the adrenal glands, resulting in Cushing's syndrome.

3. **Cushing's Disease**: This is a specific type of Cushing's syndrome caused by a pituitary adenoma that secretes excess ACTH, leading to increased cortisol production by the adrenal glands. The patient's symptoms and laboratory results are consistent with Cushing's disease, which is a rare endocrine disorder.

These diagnoses are not mutually exclusive, and the patient may have a combination of these conditions. Further evaluation and testing may be necessary to confirm the diagnosis and determine the underlying cause of the patient's symptoms.","Here are the findings and risk factors supporting each possible diagnosis:

**Cushing's Syndrome**

1. **Elevated serum cortisol levels**: The patient's 24-hour urine cortisol excretion is significantly elevated at 500 μg/day (normal: <50 μg/day), indicating excess cortisol production.
2. **Purple striae**: The patient has purple striae on her abdomen, which is a classic sign of Cushing's syndrome due to the thinning of the skin caused by excess cortisol.
3. **Weight gain and moon facies**: The patient has a history of unintentional weight gain, especially in her abdomen and face, which is consistent with Cushing's syndrome.
4. **Acne and facial hair growth**: The patient reports increased acne and facial hair growth, which are also common symptoms of Cushing's syndrome.
5. **Hypertension**: The patient has a blood pressure of 170/110 mmHg, which is a common finding in Cushing's syndrome due to the effects of excess cortisol on the cardiovascular system.

**Pituitary Adenoma with Hypercortisolism**

1. **MRI findings**: The patient's MRI shows a small adenoma in the pituitary gland, which is secreting excess ACTH.
2. **Elevated ACTH levels**: The patient's ACTH levels are raised, indicating that the pituitary adenoma is producing excess ACTH, which stimulates the adrenal glands to produce excess cortisol.
3. **Small adenoma size**: The adenoma is small, which is consistent with a microadenoma, a type of pituitary adenoma that is less than 10 mm in diameter.
4. **Symptoms consistent with Cushing's syndrome**: The patient's symptoms, including weight gain, purple striae, acne, and facial hair growth, are consistent with Cushing's syndrome.

**Cushing's Disease**

1. **Pituitary adenoma**: The patient's MRI shows a small adenoma in the pituitary gland, which is secreting excess ACTH.
2. **Elevated ACTH levels**: The patient's ACTH levels are raised, indicating that the pituitary adenoma is producing excess ACTH, which stimulates the adrenal glands to produce excess cortisol.
3. **Symptoms consistent with Cushing's syndrome**: The patient's symptoms, including weight gain, purple striae, acne, and facial hair growth, are consistent with Cushing's syndrome.
4. **History of PCOS**: The patient has a history of polycystic ovary syndrome (PCOS), which is a risk factor for developing Cushing's disease due to the potential for pituitary adenomas to develop in patients with PCOS.

These findings and risk factors support the hypothesis that the patient has Cushing's syndrome, pituitary adenoma with hypercortisolism, or Cushing's disease. Further evaluation and testing may be necessary to confirm the diagnosis and determine the underlying cause of the patient's symptoms.","Here are the findings opposing each possible diagnosis:

**Cushing's Syndrome**

1. **Lack of adrenal gland involvement**: Cushing's syndrome can be caused by adrenal gland tumors or hyperplasia, but the patient's MRI did not show any abnormalities in the adrenal glands.
2. **Normal ACTH levels**: In some cases of Cushing's syndrome, ACTH levels may be normal or even low, but in this patient, ACTH levels are elevated, which suggests a pituitary origin.
3. **No history of steroid use**: The patient denies any history of steroid use, which is a common cause of Cushing's syndrome.
4. **No family history of Cushing's syndrome**: There is no mention of a family history of Cushing's syndrome, which is a rare condition.

**Pituitary Adenoma with Hypercortisolism**

1. **Lack of other pituitary hormone abnormalities**: Pituitary adenomas can cause a variety of hormonal imbalances, but the patient's other pituitary hormone levels (e.g., prolactin, TSH, FSH) are not mentioned as being abnormal.
2. **Small adenoma size**: While the patient's adenoma is small, larger adenomas are more common in pituitary adenoma with hypercortisolism.
3. **No mention of visual field defects**: Pituitary adenomas can cause visual field defects due to compression of the optic chiasm, but the patient's visual fields are not mentioned as being abnormal.
4. **No mention of other pituitary hormone-related symptoms**: Pituitary adenomas can cause a variety of symptoms related to other pituitary hormones (e.g., prolactinoma: galactorrhea, amenorrhea; TSHoma: hypothyroidism), but these symptoms are not mentioned in the patient's history.

**Cushing's Disease**

1. **Lack of other pituitary hormone abnormalities**: Cushing's disease is a specific type of pituitary adenoma that causes Cushing's syndrome, but the patient's other pituitary hormone levels (e.g., prolactin, TSH, FSH) are not mentioned as being abnormal.
2. **No mention of other pituitary hormone-related symptoms**: Cushing's disease can cause a variety of symptoms related to other pituitary hormones (e.g., prolactinoma: galactorrhea, amenorrhea; TSHoma: hypothyroidism), but these symptoms are not mentioned in the patient's history.
3. **Small adenoma size**: While the patient's adenoma is small, larger adenomas are more common in Cushing's disease.
4. **No family history of Cushing's disease**: There is no mention of a family history of Cushing's disease, which is a rare condition.

These findings opposing each possible diagnosis suggest that the patient's condition may not be as straightforward as initially thought, and further evaluation and testing may be necessary to confirm the diagnosis and determine the underlying cause of the patient's symptoms.","Based on the patient's symptoms, laboratory results, and the findings supporting and opposing each possible diagnosis, I would make the following final diagnosis:

**Cushing's Disease**

The patient's symptoms, including weight gain, purple striae, acne, and facial hair growth, are consistent with Cushing's syndrome. The patient's elevated serum cortisol levels and 24-hour urine cortisol excretion are also consistent with Cushing's syndrome. The MRI findings of a small adenoma in the pituitary gland, which is secreting excess ACTH, are also consistent with Cushing's disease.

While the patient's lack of other pituitary hormone abnormalities and the small size of the adenoma are findings opposing Cushing's disease, they are not sufficient to rule out this diagnosis. The patient's symptoms and laboratory results are more consistent with Cushing's disease than with Cushing's syndrome or pituitary adenoma with hypercortisolism.

**Treatment Plan**

The treatment plan for Cushing's disease typically involves a multidisciplinary approach, including:

1. **Surgery**: Transsphenoidal surgery to remove the pituitary adenoma.
2. **Medications**: Medications such as ketoconazole or metyrapone to reduce cortisol production.
3. **Radiation therapy**: Radiation therapy to the pituitary gland to reduce cortisol production.
4. **Monitoring**: Regular monitoring of cortisol levels, ACTH levels, and other pituitary hormone levels to ensure that the treatment is effective and to detect any potential complications.

**Prognosis**

The prognosis for Cushing's disease is generally good, with a high success rate for surgical treatment. However, the patient's prognosis will depend on the size and location of the adenoma, as well as the patient's overall health and response to treatment.

**Follow-up**

The patient will require regular follow-up appointments to monitor their cortisol levels, ACTH levels, and other pituitary hormone levels. The patient will also need to be monitored for potential complications, such as adrenal insufficiency, osteoporosis, and hypertension.","Based on the final diagnosis of Cushing's disease, the following additional steps should be taken:

**Immediate Steps**

1. **Confirm the diagnosis**: Repeat the MRI and laboratory tests to confirm the diagnosis of Cushing's disease.
2. **Assess the patient's overall health**: Evaluate the patient's overall health, including their cardiovascular, metabolic, and endocrine systems, to determine the best course of treatment.
3. **Develop a treatment plan**: Work with the patient to develop a treatment plan that includes surgery, medications, radiation therapy, or a combination of these options.
4. **Schedule surgery**: Schedule the patient for transsphenoidal surgery to remove the pituitary adenoma.

**Pre-Surgical Steps**

1. **Optimize the patient's health**: Optimize the patient's health by managing their hypertension, diabetes, and other comorbidities.
2. **Stop medications**: Stop any medications that may interfere with the surgery or the patient's recovery.
3. **Provide education**: Educate the patient on the risks and benefits of surgery, as well as the potential complications and side effects.
4. **Obtain informed consent**: Obtain informed consent from the patient before proceeding with surgery.

**Post-Surgical Steps**

1. **Monitor the patient's recovery**: Monitor the patient's recovery closely, including their cortisol levels, ACTH levels, and other pituitary hormone levels.
2. **Manage potential complications**: Manage potential complications, such as adrenal insufficiency, osteoporosis, and hypertension.
3. **Adjust medications**: Adjust the patient's medications as needed to manage their symptoms and prevent complications.
4. **Schedule follow-up appointments**: Schedule follow-up appointments to monitor the patient's progress and adjust their treatment plan as needed.

**Long-term Management**

1. **Regular follow-up appointments**: Schedule regular follow-up appointments to monitor the patient's cortisol levels, ACTH levels, and other pituitary hormone levels.
2. **Adjust medications**: Adjust the patient's medications as needed to manage their symptoms and prevent complications.
3. **Monitor for potential complications**: Monitor the patient for potential complications, such as adrenal insufficiency, osteoporosis, and hypertension.
4. **Provide ongoing education**: Provide ongoing education to the patient on the management of Cushing's disease and the potential complications and side effects of treatment.

**Multidisciplinary Care**

1. **Endocrinologist**: Work with an endocrinologist to manage the patient's hormonal imbalances and prevent complications.
2. **Surgeon**: Work with a surgeon to perform the transsphenoidal surgery and manage any potential complications.
3. **Radiologist**: Work with a radiologist to monitor the patient's pituitary gland and adrenal glands.
4. **Primary care physician**: Work with the patient's primary care physician to manage their overall health and prevent complications.

By following these additional steps, the patient can receive comprehensive care and management for their Cushing's disease.","{""Score"":2,""Rationale"":""The answer includes Cushing's Disease and Cushing's Syndrome, which match two of the three required items in the rubric. It does not include Polycystic Ovary Syndrome or Exogenous Steroids, so only two points are awarded.""}","{""Score"":4,""Rationale"":""The answer includes Cushing's Disease and Cushing's Syndrome with several matching features from the rubric (weight gain/moon facies, purple striae, acne, facial hair, elevated cortisol, raised ACTH), earning 2 points each. It does not provide the required PCOS criteria (hirsutism, acne, irregular menses, and note that PCOS does not cause elevated cortisol or moon facies), so no points for that category. The extra mention of Pituitary Adenoma with Hypercortisolism is not in the rubric and does not affect scoring.""}","{
  ""Score"": 0,
  ""Rationale"": ""The student's answer does not match any of the concepts or opposing findings listed in the high-scoring rubric examples for Cushing's Disease, Cushing’s Syndrome/Exogenous Steroids, or PCOS, and therefore receives no points.""
}","{""Score"":2,""Rationale"":""Student correctly identified Cushing's Disease and listed the key clinical features (weight gain, purple striae, cortisol elevation) and pituitary adenoma on MRI, matching the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes a reference to working with an endocrinologist, which matches the rubric's 'Referral to endocrinology' item. It does not mention the dexamethasone suppression test or ACTH measurement, so only 2 of the 6 possible points are earned.""}",10.0
"History Of Present Illness 
A 76-year-old male presents to his primary care physician with complaints of back and thigh pain lasting for 2 weeks. He reports no pain while sitting or lying down, but walking induces severe pain in his lower back, buttocks, and calves. He also feels fatigued and slightly febrile. A referring cardiologist noted recent test results, since the onset of pain, showing a new anemia and azotemia. Notably, a few days prior to the onset of his symptoms, the patient underwent coronary angioplasty, during which he received heparin for 48 hours.
Past Medical History 
Ischemic heart disease had first been diagnosed ten years earlier, at which time a coronary artery bypass procedure was done. 
Physical Examination 
VITALS: 99.6° F.; pulse was 94/min and regular; BP was 110/88 mmHg. 
GEN: Well appearing 
CARDS: There is a grade III/VI apical systolic murmur. 
PULM: Lungs are clear to auscultation bilaterally, no wheezing, or consolidations noted. 
ABD: Soft, non-tender to palpation 
MSK: He does not have tenderness of his spine or pelvis. Spinal mobility is normal, as is the mobility of his hips. Standing is painless; however, pain is experienced in his low back, buttocks and calves within a minute of feeble running in place. The pain disappears shortly after exercise is discontinued. 
EXT: Peripheral pulses were symmetrically reduced, but palpable. The neurological examination was normal. 
SKIN: Patient has a purple, red, lacy rash over his low back and buttocks. 
Laboratory 
WBC of 11.5 x 103 cells /μL; differential of 64% segs, 20% lymphocytes, 3% monocytes, 12% eosinophils and 1% basophil. The hematocrit was 28% and the platelet count was 315 x 103 /μL. The erythrocyte sedimentation rate was 99 mm/h. Urinalysis was normal except for 2+ proteinuria. Serum creatinine was 4.0 mg/dL; sodium was 145 mEq/L; potassium 4.0 mEq/L; chloride 105 mEq/L. SGOT was 27 U/L; GGT was 90 U/L; alkaline phosphatase was 153 U/L.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Thrombotic Thrombocytopenic Purpura (TTP)**: The patient's recent coronary angioplasty, new anemia, azotemia, and thrombocytopenia (low platelet count) could be indicative of TTP. The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks also supports this diagnosis.

2. **Heparin-Induced Thrombocytopenia (HIT)**: The patient received heparin for 48 hours during coronary angioplasty, and now has a low platelet count. HIT is a known complication of heparin therapy, and the patient's symptoms, including the rash, could be indicative of this condition.

3. **Cholesterol Embolism Syndrome (CES)**: The patient's recent coronary angioplasty, new anemia, azotemia, and thrombocytopenia could also be indicative of CES. The presence of a purple, red, lacy rash on the patient's low back and buttocks, as well as the patient's symptoms of back and thigh pain, could be indicative of cholesterol emboli in the lower extremities.

These diagnoses are not mutually exclusive, and further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms.","Here are the findings and risk factors that support each possible diagnosis:

**Thrombotic Thrombocytopenic Purpura (TTP)**

* **Recent coronary angioplasty**: TTP can be triggered by certain medical procedures, including cardiac catheterization and angioplasty.
* **New anemia and azotemia**: TTP is characterized by microangiopathic hemolytic anemia, which can cause anemia and azotemia.
* **Thrombocytopenia (low platelet count)**: TTP is characterized by thrombocytopenia, which can be severe.
* **Purpura**: The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is a classic finding in TTP.
* **Elevated erythrocyte sedimentation rate (ESR)**: TTP can cause inflammation, which can lead to an elevated ESR.
* **Recent use of heparin**: Heparin can trigger TTP in some patients.

**Heparin-Induced Thrombocytopenia (HIT)**

* **Recent use of heparin**: HIT is a known complication of heparin therapy, and the patient received heparin for 48 hours during coronary angioplasty.
* **Thrombocytopenia (low platelet count)**: HIT is characterized by thrombocytopenia, which can be severe.
* **New anemia and azotemia**: HIT can cause microangiopathic hemolytic anemia, which can lead to anemia and azotemia.
* **Purpura**: The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is a classic finding in HIT.
* **Elevated ESR**: HIT can cause inflammation, which can lead to an elevated ESR.

**Cholesterol Embolism Syndrome (CES)**

* **Recent coronary angioplasty**: CES can be triggered by certain medical procedures, including cardiac catheterization and angioplasty.
* **New anemia and azotemia**: CES can cause microangiopathic hemolytic anemia, which can lead to anemia and azotemia.
* **Thrombocytopenia (low platelet count)**: CES can cause thrombocytopenia, which can be severe.
* **Purpura**: The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is a classic finding in CES.
* **Elevated ESR**: CES can cause inflammation, which can lead to an elevated ESR.
* **Reduced peripheral pulses**: CES can cause emboli in the lower extremities, which can lead to reduced peripheral pulses.
* **Proteinuria**: CES can cause renal damage, which can lead to proteinuria.

These findings and risk factors support the hypothesis that the patient's symptoms are due to one of these three possible diagnoses. Further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms.","Here are the findings that oppose each possible diagnosis, or findings that were expected but not present:

**Thrombotic Thrombocytopenic Purpura (TTP)**

* **Expected but not present: Normal renal function**: TTP can cause renal failure, but the patient's serum creatinine is only 4.0 mg/dL, which is not significantly elevated.
* **Expected but not present: Hemolysis**: TTP is characterized by microangiopathic hemolytic anemia, which can cause hemolysis. However, the patient's laboratory results do not show evidence of hemolysis.
* **Not present: Schistocytes**: TTP is characterized by the presence of schistocytes (fragmented red blood cells) on the peripheral smear. However, the patient's peripheral smear is not mentioned.
* **Not present: Fever**: TTP can cause fever, but the patient's temperature is only slightly elevated (99.6°F).

**Heparin-Induced Thrombocytopenia (HIT)**

* **Expected but not present: Thrombosis**: HIT is characterized by the formation of antibodies that activate platelets, leading to thrombosis. However, the patient's laboratory results do not show evidence of thrombosis.
* **Not present: Thrombosis in unusual locations**: HIT can cause thrombosis in unusual locations, such as the skin, kidneys, or lungs. However, the patient's symptoms and laboratory results do not suggest thrombosis in these locations.
* **Not present: High levels of anti-heparin antibodies**: HIT is characterized by the presence of high levels of anti-heparin antibodies. However, the patient's laboratory results do not mention the presence of these antibodies.

**Cholesterol Embolism Syndrome (CES)**

* **Expected but not present: High levels of cholesterol crystals**: CES is characterized by the presence of high levels of cholesterol crystals in the blood. However, the patient's laboratory results do not mention the presence of these crystals.
* **Not present: Emboli in unusual locations**: CES can cause emboli in unusual locations, such as the brain, kidneys, or lungs. However, the patient's symptoms and laboratory results do not suggest emboli in these locations.
* **Not present: High levels of inflammatory markers**: CES can cause inflammation, which can lead to high levels of inflammatory markers. However, the patient's laboratory results do not show evidence of inflammation.

These findings oppose each possible diagnosis, or findings that were expected but not present. Further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

The patient's recent use of heparin, thrombocytopenia (low platelet count), new anemia and azotemia, and purpura (purple, red, lacy rash on the low back and buttocks) are all consistent with HIT. The patient's symptoms and laboratory results do not strongly suggest TTP or CES, and the findings that oppose each of these diagnoses are more compelling.

**Reasoning:**

* The patient's recent use of heparin is a strong risk factor for HIT.
* The patient's thrombocytopenia (low platelet count) is consistent with HIT.
* The patient's new anemia and azotemia could be caused by HIT, which can lead to microangiopathic hemolytic anemia.
* The patient's purpura (purple, red, lacy rash on the low back and buttocks) is a classic finding in HIT.
* The patient's laboratory results do not show evidence of hemolysis, schistocytes, or high levels of anti-heparin antibodies, which are not typical of HIT.

**Treatment:**

* Discontinue heparin and start an alternative anticoagulant, such as argatroban or bivalirudin.
* Monitor the patient's platelet count and adjust the anticoagulant as needed.
* Consider administering corticosteroids to reduce inflammation and prevent further thrombocytopenia.
* Monitor the patient's renal function and adjust the anticoagulant as needed to prevent further renal damage.

**Follow-up:**

* Monitor the patient's platelet count and adjust the anticoagulant as needed.
* Monitor the patient's renal function and adjust the anticoagulant as needed to prevent further renal damage.
* Consider repeating the patient's laboratory tests to confirm the diagnosis of HIT and to monitor the patient's response to treatment.","Based on the final diagnosis of Heparin-Induced Thrombocytopenia (HIT), the following additional steps should be taken:

**Immediate Steps:**

1. **Discontinue heparin**: Immediately discontinue heparin and start an alternative anticoagulant, such as argatroban or bivalirudin.
2. **Monitor platelet count**: Monitor the patient's platelet count closely to ensure that it is increasing and to adjust the anticoagulant as needed.
3. **Assess for thrombosis**: Assess the patient for signs of thrombosis, such as pain, swelling, or decreased mobility, and consider imaging studies to confirm the presence of thrombosis.
4. **Provide supportive care**: Provide supportive care, such as pain management and wound care, as needed.

**Short-term Steps:**

1. **Repeat laboratory tests**: Repeat the patient's laboratory tests, including a complete blood count (CBC), platelet count, and coagulation studies, to confirm the diagnosis of HIT and to monitor the patient's response to treatment.
2. **Monitor renal function**: Monitor the patient's renal function closely to ensure that it is not worsening and to adjust the anticoagulant as needed.
3. **Consider corticosteroids**: Consider administering corticosteroids to reduce inflammation and prevent further thrombocytopenia.
4. **Review medication list**: Review the patient's medication list to ensure that there are no other medications that may be contributing to the patient's thrombocytopenia.

**Long-term Steps:**

1. **Follow-up appointments**: Schedule follow-up appointments with the patient to monitor their progress and adjust the anticoagulant as needed.
2. **Monitor for HIT recurrence**: Monitor the patient for signs of HIT recurrence, such as a decrease in platelet count or the development of new thrombosis.
3. **Consider alternative anticoagulants**: Consider alternative anticoagulants, such as direct oral anticoagulants (DOACs), for future use.
4. **Educate patient and family**: Educate the patient and their family about the diagnosis of HIT, its treatment, and the importance of monitoring for signs of recurrence.

**Additional Considerations:**

1. **Report HIT to the FDA**: Report the diagnosis of HIT to the FDA to help identify potential causes and to improve patient safety.
2. **Review hospital policies**: Review hospital policies and procedures for HIT diagnosis and treatment to ensure that they are up-to-date and effective.
3. **Provide education to healthcare team**: Provide education to the healthcare team about HIT diagnosis and treatment to ensure that they are aware of the risks and benefits of anticoagulant therapy.","{""Score"":1,""Rationale"":""Only 'Cholesterol Embolism' matches an item in the rubric; the other two diagnoses are not listed in the high-scoring example, so they receive no points.""}","{""Score"":2,""Rationale"":""Student correctly identified cholesterol embolism and listed several matching features (recent PCI, rash, peripheral involvement, renal involvement), but omitted other key rubric items (eosinophilia, known CAD). The other two diagnoses (TTP, HIT) are not in the rubric, so only the cholesterol embolism earns points, resulting in 2/6.""}","{""Score"":0,""Rationale"":""Student answer does not match any of the specific concepts or bullet points listed in the high scoring example for the three required diagnoses; therefore no points are awarded.""}","{""Score"":0,""Rationale"":""The student's answer was Heparin-Induced Thrombocytopenia, which does not match the required answer 'Cholesterol embolism' in the rubric; therefore no points are awarded.""}","{""Score"":0,""Rationale"":""The student's answer does not mention any of the rubric concepts: arterial ultrasounds/ABI, urine analysis for casts/eosinophils/nephrology consult, or renal biopsy. Therefore no points are awarded.""}",3.0
"History of Present Illness
A 42-year-old male presents with chronic burning pain in his hands and feet, which has worsened over the past year. He has frequent episodes of abdominal cramping and diarrhea. He reports fatigue, decreased exercise tolerance, and intermittent difficulty with vision. He recalls a history of a similar condition in his older brother, who died from kidney failure at the age of 48. 

Past Medical History
The patient has been diagnosed with chronic kidney disease of unknown etiology. He also has a history of hearing loss and occasional headaches. There is a history of diabetes and hypertension. 

Physical Examination
VITALS: BP 150/90 mmHg, pulse 82/min, temperature 98.6°F. 
GEN: Thin, mildly fatigued. 
HEENT: Corneal opacities visible on slit lamp examination. 
CARDIAC: No murmurs or gallops. 
PULM: Clear to auscultation bilaterally. 
ABD: Non-tender, hepatosplenomegaly noted. 
EXT: Angiokeratomas on the lower abdomen and upper thighs. 
SKIN: No significant rashes. 

Laboratory Results
Serum creatinine is elevated at 2.8 mg/dL. Urinalysis shows 3+ proteinuria with no red blood cells. Alpha-galactosidase A activity in plasma is significantly reduced.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Fabry Disease**: This is a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, which leads to the accumulation of globotriaosylceramide (Gb3) in various tissues, including the kidneys, heart, and nervous system. The patient's reduced alpha-galactosidase A activity in plasma and the presence of angiokeratomas (small, red or purple spots on the skin) are consistent with Fabry disease. The patient's symptoms, including chronic burning pain in the hands and feet, abdominal cramping, diarrhea, fatigue, and vision difficulties, are also typical of Fabry disease.

2. **Diabetic Nephropathy**: The patient has a history of diabetes, which is a common cause of chronic kidney disease. Diabetic nephropathy can lead to proteinuria (excess protein in the urine), elevated serum creatinine, and other symptoms such as fatigue and decreased exercise tolerance.

3. **Nephropathy due to Hypertension**: The patient's history of hypertension and elevated serum creatinine suggest that his kidney disease may be related to high blood pressure. Hypertension can cause damage to the kidneys, leading to proteinuria, elevated serum creatinine, and other symptoms such as fatigue and decreased exercise tolerance.

However, considering the patient's family history of a similar condition and the presence of corneal opacities, Fabry disease is the most likely diagnosis.","Here are the findings and risk factors that support each possible diagnosis:

**Fabry Disease**

1. **Reduced alpha-galactosidase A activity**: The patient's plasma alpha-galactosidase A activity is significantly reduced, which is a hallmark of Fabry disease.
2. **Angiokeratomas**: The presence of angiokeratomas on the lower abdomen and upper thighs is a characteristic skin manifestation of Fabry disease.
3. **Corneal opacities**: The patient's corneal opacities, visible on slit lamp examination, are a common finding in Fabry disease.
4. **Family history**: The patient's older brother died from kidney failure at the age of 48, which suggests a possible genetic component to the patient's condition.
5. **Chronic burning pain**: The patient's chronic burning pain in the hands and feet is a common symptom of Fabry disease.
6. **Abdominal cramping and diarrhea**: The patient's gastrointestinal symptoms are also consistent with Fabry disease.

**Diabetic Nephropathy**

1. **History of diabetes**: The patient has a history of diabetes, which is a major risk factor for diabetic nephropathy.
2. **Elevated serum creatinine**: The patient's elevated serum creatinine suggests kidney damage, which is consistent with diabetic nephropathy.
3. **Proteinuria**: The patient's proteinuria (excess protein in the urine) is a common finding in diabetic nephropathy.
4. **Hypertension**: The patient's hypertension is a risk factor for diabetic nephropathy.

**Nephropathy due to Hypertension**

1. **Hypertension**: The patient's hypertension is a major risk factor for nephropathy.
2. **Elevated serum creatinine**: The patient's elevated serum creatinine suggests kidney damage, which is consistent with nephropathy due to hypertension.
3. **Proteinuria**: The patient's proteinuria (excess protein in the urine) is a common finding in nephropathy due to hypertension.
4. **Kidney disease of unknown etiology**: The patient's kidney disease is of unknown etiology, which could be consistent with nephropathy due to hypertension.

However, considering the patient's family history, corneal opacities, and reduced alpha-galactosidase A activity, Fabry disease is the most likely diagnosis.","Here are the findings that oppose each possible diagnosis:

**Fabry Disease**

1. **Lack of specific Fabry disease-related symptoms**: While the patient has chronic burning pain, abdominal cramping, and diarrhea, these symptoms are not specific to Fabry disease and could be caused by other conditions.
2. **No mention of cardiac involvement**: Fabry disease often causes cardiac involvement, such as hypertrophic cardiomyopathy or coronary artery disease. The patient's cardiac examination is normal, which suggests that cardiac involvement may not be present.
3. **No mention of hearing loss progression**: Fabry disease can cause progressive hearing loss, but the patient's hearing loss is not mentioned as being progressive.
4. **Normal kidney function in early stages**: Fabry disease often causes kidney damage in the early stages, but the patient's kidney disease is already advanced (elevated serum creatinine and proteinuria).
5. **No mention of gastrointestinal bleeding**: Fabry disease can cause gastrointestinal bleeding, but the patient's gastrointestinal symptoms are not mentioned as being severe enough to cause bleeding.

**Diabetic Nephropathy**

1. **Normal blood glucose levels**: The patient's blood glucose levels are not mentioned, but if they are normal, it would suggest that diabetic nephropathy is less likely.
2. **No mention of retinopathy**: Diabetic retinopathy is a common complication of diabetes, but the patient's eye examination is not mentioned as showing any signs of retinopathy.
3. **Normal kidney function in early stages**: Diabetic nephropathy often causes kidney damage in the early stages, but the patient's kidney disease is already advanced (elevated serum creatinine and proteinuria).
4. **No mention of neuropathy**: Diabetic neuropathy is a common complication of diabetes, but the patient's symptoms do not suggest neuropathy.
5. **Family history of kidney disease**: While the patient's family history of kidney disease is a risk factor for diabetic nephropathy, it is not a definitive indicator of the condition.

**Nephropathy due to Hypertension**

1. **Normal blood pressure in early stages**: Nephropathy due to hypertension often causes kidney damage in the early stages, but the patient's hypertension is not mentioned as being severe enough to cause kidney damage.
2. **No mention of proteinuria in early stages**: Nephropathy due to hypertension often causes proteinuria in the early stages, but the patient's proteinuria is already severe (3+ proteinuria).
3. **No mention of hematuria**: Nephropathy due to hypertension often causes hematuria (blood in the urine), but the patient's urinalysis does not mention hematuria.
4. **No mention of kidney size**: Nephropathy due to hypertension often causes kidney enlargement, but the patient's kidney size is not mentioned.
5. **Family history of kidney disease**: While the patient's family history of kidney disease is a risk factor for nephropathy due to hypertension, it is not a definitive indicator of the condition.

These findings suggest that while each diagnosis is possible, there are some inconsistencies that make each diagnosis less likely.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Fabry Disease**

The patient's reduced alpha-galactosidase A activity, angiokeratomas, corneal opacities, and family history of a similar condition all strongly suggest Fabry disease. While there are some inconsistencies, such as the lack of specific Fabry disease-related symptoms and the absence of cardiac involvement, these findings are not sufficient to rule out the diagnosis. The patient's advanced kidney disease, proteinuria, and elevated serum creatinine are also consistent with Fabry disease.

**Supporting evidence:**

* Reduced alpha-galactosidase A activity
* Angiokeratomas
* Corneal opacities
* Family history of a similar condition
* Chronic burning pain
* Abdominal cramping and diarrhea

**Opposing evidence:**

* Lack of specific Fabry disease-related symptoms
* No mention of cardiac involvement
* No mention of hearing loss progression
* Normal kidney function in early stages (not applicable, as the patient's kidney disease is already advanced)

**Differential diagnosis:**

* Diabetic nephropathy: While the patient has a history of diabetes, the presence of Fabry disease-related symptoms and laboratory findings makes this diagnosis less likely.
* Nephropathy due to hypertension: The patient's hypertension is a risk factor for nephropathy, but the presence of Fabry disease-related symptoms and laboratory findings makes this diagnosis less likely.

**Management:**

* Enzyme replacement therapy (ERT) to replace the deficient alpha-galactosidase A enzyme
* Pain management for chronic burning pain
* Management of gastrointestinal symptoms
* Regular monitoring of kidney function and proteinuria
* Regular monitoring of cardiac function and hearing loss

**Genetic counseling:**

* The patient's family members should be screened for Fabry disease
* Genetic counseling should be provided to the patient and their family members to discuss the risks and benefits of genetic testing and ERT.","Based on the final diagnosis of Fabry disease, the following additional steps should be taken:

**Initial Steps:**

1. **Confirm the diagnosis**: Confirm the diagnosis of Fabry disease through genetic testing, such as sequencing of the GLA gene.
2. **Enzyme replacement therapy (ERT)**: Start ERT to replace the deficient alpha-galactosidase A enzyme.
3. **Pain management**: Manage the patient's chronic burning pain with pain medications, such as gabapentin or pregabalin.
4. **Gastrointestinal management**: Manage the patient's gastrointestinal symptoms with medications, such as antacids or proton pump inhibitors.
5. **Regular monitoring**: Regularly monitor the patient's kidney function, proteinuria, and cardiac function.

**Long-term Management:**

1. **ERT dosing**: Adjust the ERT dosing as needed to maintain optimal enzyme levels.
2. **Pain management**: Continue pain management with medications and consider alternative therapies, such as acupuncture or physical therapy.
3. **Gastrointestinal management**: Continue gastrointestinal management with medications and consider alternative therapies, such as dietary changes or probiotics.
4. **Regular monitoring**: Regularly monitor the patient's kidney function, proteinuria, and cardiac function.
5. **Genetic counseling**: Provide genetic counseling to the patient and their family members to discuss the risks and benefits of genetic testing and ERT.

**Specialized Care:**

1. **Cardiology**: Refer the patient to a cardiologist for regular monitoring of cardiac function and management of cardiac complications.
2. **Nephrology**: Refer the patient to a nephrologist for regular monitoring of kidney function and management of kidney complications.
3. **Pain management specialist**: Refer the patient to a pain management specialist for management of chronic pain.
4. **Gastroenterology**: Refer the patient to a gastroenterologist for management of gastrointestinal symptoms.

**Patient Education:**

1. **Disease education**: Educate the patient about Fabry disease, its symptoms, and its management.
2. **ERT education**: Educate the patient about ERT, its benefits, and its risks.
3. **Pain management education**: Educate the patient about pain management options and their benefits and risks.
4. **Gastrointestinal management education**: Educate the patient about gastrointestinal management options and their benefits and risks.

**Family Support:**

1. **Genetic counseling**: Provide genetic counseling to the patient's family members to discuss the risks and benefits of genetic testing and ERT.
2. **Family education**: Educate the patient's family members about Fabry disease, its symptoms, and its management.
3. **Family support**: Provide emotional support to the patient's family members and help them cope with the diagnosis.

By following these steps, the patient with Fabry disease can receive optimal care and management, and their quality of life can be improved.","{""Score"": 1.5, ""Rationale"": ""Student correctly identified Fabry Disease (1 mark) and Diabetic Nephropathy (0.5 mark); other diagnoses (Hypertension-related nephropathy) are not listed in the rubric, so no points for them.""}","{""Score"":4,""Rationale"":""The answer includes the key concepts for Fabry Disease (reduced enzyme activity, angiokeratomas, corneal opacities, family history, burning pain) matching the high‑scoring example, and it lists Diabetic Related Complications with appropriate supporting findings, also matching the rubric. It does not mention CKD secondary to Alport Syndrome or Polyarteritis Nodosa, so no points are awarded for those items.""}","{""Score"":0,""Rationale"":""Student answer does not match any of the required opposing findings for the four diagnoses listed in the rubric; diagnoses and arguments differ from the high-scoring example.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Fabry Disease and includes the key clinical features from the rubric (burning pain, angiokeratomas, corneal opacities, family history, and reduced alpha‑galactosidase A activity), matching the high‑scoring example.""}","{""Score"":6,""Rationale"":""The answer includes genetic testing to confirm Fabry disease, initiation of enzyme replacement therapy, and regular monitoring of renal (kidney) function, matching all three rubric items.""}",13.5
"History of Present Illness
A 55-year-old female presents with a 3-month history of progressive difficulty swallowing, drooping of her eyelids, and muscle weakness. She reports that her symptoms are worse by the end of the day and improve with rest. She has also noticed difficulty speaking and has frequent choking episodes when drinking liquids. There is no associated pain, and she denies any other systemic symptoms.

  Past Medical History
She has no significant medical history but was diagnosed with hypothyroidism 5 years ago and has been on levothyroxine since then. Family history is unremarkable.

  Physical Examination
VITALS: BP 130/80 mmHg, pulse 75/min, temperature 98.7°F. 
GEN: Well-appearing, no distress. 
HEENT: Ptosis noted in both eyelids, worse on the right side. 
PULM: Clear to auscultation bilaterally. 
NEURO: Proximal muscle weakness
EXT: No edema

  Laboratory Results
Acetylcholine receptor antibodies are positive. Serum creatine kinase (CK) is normal.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Myasthenia Gravis (MG)**: This is an autoimmune disease characterized by weakness and rapid fatigue of the muscles under voluntary control. The presence of ptosis (drooping eyelids), proximal muscle weakness, and improvement of symptoms with rest are classic features of MG. The positive acetylcholine receptor antibodies further support this diagnosis.

2. **Lambert-Eaton Myasthenic Syndrome (LEMS)**: This is another autoimmune disease that affects the neuromuscular junction, similar to MG. However, LEMS typically presents with muscle weakness that worsens with activity and improves with rest, which is the opposite of MG. The patient's symptoms could be consistent with LEMS, but the presence of ptosis and the specific laboratory results are more suggestive of MG.

3. **Muscular Dystrophy**: This is a group of genetic disorders characterized by progressive muscle weakness and wasting. However, the patient's symptoms and laboratory results do not strongly suggest a muscular dystrophy. The normal serum creatine kinase (CK) level is particularly inconsistent with a muscular dystrophy diagnosis, as CK levels are typically elevated in these conditions.

It's worth noting that the patient's history of hypothyroidism and the presence of acetylcholine receptor antibodies may also suggest a connection between the patient's autoimmune disease and her thyroid condition. Further investigation and consultation with a specialist may be necessary to confirm the diagnosis and develop an effective treatment plan.","Here are the findings and risk factors that support each possible diagnosis:

**Myasthenia Gravis (MG)**

1. **Symptoms**: The patient's symptoms, such as ptosis, proximal muscle weakness, difficulty speaking, and frequent choking episodes, are classic features of MG.
2. **Acetylcholine receptor antibodies**: The presence of acetylcholine receptor antibodies is a hallmark of MG and is found in approximately 85% of patients with the disease.
3. **Improvement with rest**: The patient's symptoms improve with rest, which is consistent with the fluctuating nature of MG.
4. **No pain**: The absence of pain is also consistent with MG, as pain is not typically a feature of the disease.
5. **Family history**: Although the patient's family history is unremarkable, MG can occur in families, and some patients may have a genetic predisposition to the disease.

**Lambert-Eaton Myasthenic Syndrome (LEMS)**

1. **Symptoms**: The patient's symptoms, such as muscle weakness that worsens with activity and improves with rest, are consistent with LEMS.
2. **Autoimmune etiology**: LEMS is an autoimmune disease, and the patient's symptoms and laboratory results suggest an autoimmune etiology.
3. **Normal CK level**: The patient's normal CK level is consistent with LEMS, as CK levels are typically normal in this disease.
4. **Association with small cell lung cancer**: LEMS is often associated with small cell lung cancer, and the patient's age and symptoms make this a possible consideration.
5. **Electrophysiological studies**: Electrophysiological studies, such as electromyography (EMG) and nerve conduction studies (NCS), may show characteristic abnormalities in LEMS.

**Muscular Dystrophy**

1. **Family history**: Although the patient's family history is unremarkable, some muscular dystrophies can occur in families, and a family history of muscle weakness or wasting may be present.
2. **Muscle weakness**: The patient's muscle weakness is a feature of muscular dystrophy, but the pattern and distribution of weakness are not typical of this disease.
3. **Normal CK level**: The patient's normal CK level is inconsistent with most forms of muscular dystrophy, as CK levels are typically elevated in these conditions.
4. **Progressive muscle weakness**: The patient's symptoms suggest a progressive course, which is consistent with muscular dystrophy.
5. **Electrophysiological studies**: Electrophysiological studies, such as EMG and NCS, may show characteristic abnormalities in muscular dystrophy.

It's worth noting that the patient's symptoms and laboratory results are more consistent with Myasthenia Gravis (MG) than with the other two possible diagnoses. Further investigation and consultation with a specialist may be necessary to confirm the diagnosis and develop an effective treatment plan.","Here are the findings that oppose each possible diagnosis:

**Myasthenia Gravis (MG)**

1. **Normal CK level**: Although the patient's normal CK level is not uncommon in MG, it is not typical of the disease. Elevated CK levels are often seen in MG, especially in patients with thymoma or those who have had recent exacerbations.
2. **No thymoma or thymic hyperplasia**: The patient's lack of thymoma or thymic hyperplasia is unusual, as these conditions are often associated with MG.
3. **No significant improvement with medication**: The patient's symptoms may not have improved significantly with medication, which is not typical of MG. Most patients with MG experience significant improvement with anticholinesterase inhibitors or immunosuppressive therapy.
4. **No significant change in symptoms with sleep**: The patient's symptoms may not have improved significantly with sleep, which is not typical of MG. Most patients with MG experience significant improvement with sleep.
5. **No significant change in symptoms with exercise**: The patient's symptoms may not have worsened significantly with exercise, which is not typical of MG. Most patients with MG experience significant worsening of symptoms with exercise.

**Lambert-Eaton Myasthenic Syndrome (LEMS)**

1. **Presence of acetylcholine receptor antibodies**: The patient's presence of acetylcholine receptor antibodies is not typical of LEMS, as these antibodies are more commonly associated with MG.
2. **No small cell lung cancer**: The patient's lack of small cell lung cancer is unusual, as this condition is often associated with LEMS.
3. **No significant improvement with calcium channel blockers**: The patient's symptoms may not have improved significantly with calcium channel blockers, which is not typical of LEMS. Most patients with LEMS experience significant improvement with these medications.
4. **No significant worsening of symptoms with exercise**: The patient's symptoms may not have worsened significantly with exercise, which is not typical of LEMS. Most patients with LEMS experience significant worsening of symptoms with exercise.
5. **No significant change in symptoms with sleep**: The patient's symptoms may not have improved significantly with sleep, which is not typical of LEMS. Most patients with LEMS experience significant improvement with sleep.

**Muscular Dystrophy**

1. **Normal CK level**: The patient's normal CK level is inconsistent with most forms of muscular dystrophy, as CK levels are typically elevated in these conditions.
2. **No significant muscle weakness in childhood**: The patient's lack of significant muscle weakness in childhood is unusual, as most forms of muscular dystrophy present in childhood.
3. **No significant family history**: The patient's lack of significant family history is unusual, as many forms of muscular dystrophy are inherited in an autosomal dominant or recessive pattern.
4. **No significant change in symptoms with exercise**: The patient's symptoms may not have worsened significantly with exercise, which is not typical of muscular dystrophy. Most patients with muscular dystrophy experience significant worsening of symptoms with exercise.
5. **No significant change in symptoms with sleep**: The patient's symptoms may not have improved significantly with sleep, which is not typical of muscular dystrophy. Most patients with muscular dystrophy experience significant improvement with sleep.

It's worth noting that the patient's symptoms and laboratory results are more consistent with Myasthenia Gravis (MG) than with the other two possible diagnoses. Further investigation and consultation with a specialist may be necessary to confirm the diagnosis and develop an effective treatment plan.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Myasthenia Gravis (MG)**

The patient's symptoms, such as ptosis, proximal muscle weakness, difficulty speaking, and frequent choking episodes, are classic features of MG. The presence of acetylcholine receptor antibodies is a hallmark of MG and is found in approximately 85% of patients with the disease. The patient's symptoms improve with rest, which is consistent with the fluctuating nature of MG. The normal CK level is not uncommon in MG, and the patient's lack of thymoma or thymic hyperplasia does not rule out the diagnosis.

The findings that oppose LEMS and muscular dystrophy are also consistent with MG. The patient's symptoms do not worsen significantly with exercise, which is not typical of LEMS. The patient's normal CK level and lack of significant muscle weakness in childhood are also inconsistent with muscular dystrophy.

Therefore, based on the patient's symptoms and laboratory results, I would make the final diagnosis of Myasthenia Gravis (MG).

**Treatment Plan**

The treatment plan for MG typically involves a combination of medications, including:

1. **Anticholinesterase inhibitors**: Such as pyridostigmine, which can help improve muscle strength and reduce symptoms.
2. **Immunosuppressive therapy**: Such as corticosteroids or azathioprine, which can help reduce the production of acetylcholine receptor antibodies and improve symptoms.
3. **Plasmapheresis**: A procedure that involves removing antibodies from the blood, which can help improve symptoms in severe cases.
4. **Thymectomy**: A surgical procedure that involves removing the thymus gland, which can help reduce the production of acetylcholine receptor antibodies and improve symptoms.

The patient will need to be monitored regularly to assess the effectiveness of treatment and make any necessary adjustments.","Based on the final diagnosis of Myasthenia Gravis (MG), the following additional steps should be taken:

**Initial Steps**

1. **Confirm the diagnosis**: Repeat the acetylcholine receptor antibody test to confirm the presence of antibodies.
2. **Thyroid function tests**: Repeat the thyroid function tests to ensure that the patient's hypothyroidism is well-controlled.
3. **Electrophysiological studies**: Perform electromyography (EMG) and nerve conduction studies (NCS) to assess muscle strength and nerve function.
4. **Imaging studies**: Perform chest X-rays and computed tomography (CT) scans to assess the size and shape of the thymus gland.

**Treatment Optimization**

1. **Adjust medication dosages**: Adjust the dosages of anticholinesterase inhibitors and immunosuppressive therapy to optimize symptom control.
2. **Monitor side effects**: Monitor the patient for side effects of medication, such as muscle weakness, fatigue, and respiratory problems.
3. **Thymectomy**: Consider thymectomy as a treatment option, especially if the patient has a large thymus gland or significant antibody production.
4. **Plasmapheresis**: Consider plasmapheresis as a treatment option for severe cases of MG.

**Long-term Management**

1. **Regular follow-up**: Schedule regular follow-up appointments to monitor the patient's symptoms and adjust treatment as needed.
2. **Lifestyle modifications**: Encourage the patient to make lifestyle modifications, such as avoiding heavy lifting and bending, to reduce the risk of exacerbating symptoms.
3. **Emergency preparedness**: Educate the patient on emergency preparedness, such as knowing the signs of respiratory failure and having a plan in place for emergency situations.
4. **Support groups**: Refer the patient to support groups to connect with others who have MG and share experiences.

**Research and Clinical Trials**

1. **Clinical trials**: Consider enrolling the patient in clinical trials to evaluate new treatments for MG.
2. **Research studies**: Participate in research studies to better understand the pathophysiology of MG and develop new treatments.

By taking these additional steps, the patient can receive optimal care and management for their Myasthenia Gravis.","{""Score"":2,""Rationale"":""The answer correctly includes Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome, which match two of the three required concepts. It does not include Hypothyroid Myopathy and adds Muscular Dystrophy, which is not in the rubric, so only 2 points are awarded.""}","{""Score"":0,""Rationale"":""The answer includes some MG and LEMS features but omits key rubric concepts such as the decremental EMG response for MG, the negative acetylcholine receptor antibodies and facilitation EMG response for LEMS, and does not address hypothyroid myopathy at all. Therefore no points are awarded.""}","{""Score"":0,""Rationale"":""The student's answer does not contain any of the specific opposing findings listed in the rubric for Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, or Hypothyroid Myopathy; therefore no points are awarded.""}","{""Score"":2,""Rationale"":""Student correctly identified Myasthenia Gravis with supporting symptoms and acetylcholine receptor antibodies, matching the high‑scoring example.""}","{""Score"":4,""Rationale"":""The answer includes two rubric items: CT scan of the chest and thyroid function assessment, each worth 2 points. It does not mention the Edrophonium (Tensilon) test, so no points for that item.""}",8.0
"History of Present Illness
A 41-year-old male presents with a 4-week history of chronic sinus congestion, bloody nasal discharge, and persistent cough with hemoptysis. He also complains of joint pain and swelling in both knees and ankles. He reports unintentional weight loss of 8 kg over the last 2 months. He denies any recent trauma, travel, or exposure to sick contacts.

  Past Medical History
The patient has no significant medical history but was previously healthy. He has no known drug allergies and does not smoke or drink alcohol.

  Physical Examination
VITALS: BP 120/78 mmHg, pulse 88/min, temperature 99.2°F. 
GEN: Well-appearing but fatigued. 
HEENT: Nasal mucosal ulcerations, bloody discharge from both nostrils. 
PULM: Bilateral rales in the lungs. 
ABD: Soft, non-tender. 
EXT: Swelling in both knees and ankles, with mild erythema. 
SKIN: No rashes.

  Laboratory Results
WBC count is 12.8 x 103/μL, with a mild left shift. ESR is elevated at 75 mm/h. Serum creatinine is 1.5 mg/dL, and urinalysis shows 1+ proteinuria with RBC casts. c-ANCA is positive. Chest CT shows multiple nodular lung infiltrates and cavities.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Granulomatosis with Polyangiitis (GPA)**: This is a form of vasculitis that affects small- and medium-sized blood vessels, often presenting with respiratory symptoms such as sinus congestion, bloody nasal discharge, and hemoptysis, as well as systemic symptoms like joint pain and swelling. The presence of c-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibodies) is a strong indicator of GPA. The patient's laboratory results, including elevated ESR and mild left shift, also support this diagnosis.

2. **Eosinophilic Granulomatosis with Polyangiitis (EGPA)**: This is another form of vasculitis that affects small- and medium-sized blood vessels, often presenting with respiratory symptoms and systemic symptoms. EGPA is characterized by the presence of eosinophilia and asthma, but the patient's symptoms do not mention asthma. However, the presence of c-ANCA can also be seen in EGPA, making it a possible diagnosis.

3. **Lymphomatoid Granulomatosis (LG)**: This is a rare and aggressive form of lymphoma that affects the lungs and other organs, often presenting with respiratory symptoms such as hemoptysis and sinus congestion. The patient's chest CT showing multiple nodular lung infiltrates and cavities is consistent with LG. However, the presence of c-ANCA is not typically associated with LG, making this diagnosis less likely.

It's essential to note that these diagnoses are not mutually exclusive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Here are the findings and risk factors that support each possible diagnosis:

**Granulomatosis with Polyangiitis (GPA)**

1. **Respiratory symptoms**: The patient's symptoms of chronic sinus congestion, bloody nasal discharge, and hemoptysis are consistent with GPA.
2. **C-ANCA positivity**: The presence of c-ANCA is a strong indicator of GPA, as it is found in approximately 90% of patients with this condition.
3. **Systemic symptoms**: The patient's joint pain and swelling, as well as unintentional weight loss, are consistent with GPA.
4. **Laboratory results**: The patient's elevated ESR and mild left shift are consistent with GPA.
5. **Kidney involvement**: The presence of 1+ proteinuria with RBC casts suggests kidney involvement, which is common in GPA.

**Eosinophilic Granulomatosis with Polyangiitis (EGPA)**

1. **Respiratory symptoms**: The patient's symptoms of chronic sinus congestion and hemoptysis are consistent with EGPA.
2. **C-ANCA positivity**: While c-ANCA is more commonly associated with GPA, it can also be seen in EGPA.
3. **Systemic symptoms**: The patient's joint pain and swelling, as well as unintentional weight loss, are consistent with EGPA.
4. **Elevated ESR**: The patient's elevated ESR is consistent with EGPA.
5. **Absence of asthma**: While asthma is a common feature of EGPA, the patient's symptoms do not mention asthma.

**Lymphomatoid Granulomatosis (LG)**

1. **Respiratory symptoms**: The patient's symptoms of hemoptysis and sinus congestion are consistent with LG.
2. **Chest CT findings**: The patient's chest CT showing multiple nodular lung infiltrates and cavities is consistent with LG.
3. **Unintentional weight loss**: The patient's unintentional weight loss is consistent with LG.
4. **Kidney involvement**: The presence of 1+ proteinuria with RBC casts suggests kidney involvement, which is common in LG.
5. **Absence of c-ANCA**: The patient's c-ANCA negativity makes LG a less likely diagnosis, as c-ANCA is not typically associated with LG.

It's essential to note that these findings and risk factors are not exhaustive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Here are the findings that oppose each possible diagnosis:

**Granulomatosis with Polyangiitis (GPA)**

1. **Absence of asthma**: GPA often presents with asthma, but the patient's symptoms do not mention asthma.
2. **Lack of granulomatous inflammation**: GPA is characterized by granulomatous inflammation, but the patient's laboratory results do not mention granulomatous inflammation.
3. **Negative p-ANCA**: While c-ANCA is a strong indicator of GPA, p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies) is more commonly associated with GPA. The patient's p-ANCA status is not mentioned, but a negative result would oppose this diagnosis.
4. **No mention of skin involvement**: GPA often presents with skin involvement, such as purpura or livedo reticularis, but the patient's skin examination is normal.
5. **No mention of gastrointestinal involvement**: GPA often presents with gastrointestinal involvement, such as abdominal pain or diarrhea, but the patient's symptoms do not mention gastrointestinal involvement.

**Eosinophilic Granulomatosis with Polyangiitis (EGPA)**

1. **Absence of asthma**: EGPA is often characterized by asthma, but the patient's symptoms do not mention asthma.
2. **Negative c-ANCA**: While c-ANCA can be seen in EGPA, a negative result would oppose this diagnosis.
3. **Lack of eosinophilia**: EGPA is characterized by eosinophilia, but the patient's laboratory results do not mention eosinophilia.
4. **No mention of cardiac involvement**: EGPA often presents with cardiac involvement, such as pericarditis or myocarditis, but the patient's symptoms do not mention cardiac involvement.
5. **No mention of neurological involvement**: EGPA often presents with neurological involvement, such as seizures or neuropathy, but the patient's symptoms do not mention neurological involvement.

**Lymphomatoid Granulomatosis (LG)**

1. **Negative c-ANCA**: LG is not typically associated with c-ANCA, so a positive result would oppose this diagnosis.
2. **Lack of lymphadenopathy**: LG often presents with lymphadenopathy, but the patient's physical examination does not mention lymphadenopathy.
3. **No mention of fever**: LG often presents with fever, but the patient's temperature is only slightly elevated.
4. **No mention of weight loss**: While unintentional weight loss is a common feature of LG, the patient's weight loss is not mentioned as being significant.
5. **No mention of night sweats**: LG often presents with night sweats, but the patient's symptoms do not mention night sweats.

It's essential to note that these findings opposing each diagnosis are not exhaustive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Based on the patient's symptoms, laboratory results, and physical examination, I would make the following final diagnosis:

**Granulomatosis with Polyangiitis (GPA)**

The patient's symptoms of chronic sinus congestion, bloody nasal discharge, and hemoptysis are consistent with GPA. The presence of c-ANCA is a strong indicator of GPA, and the patient's laboratory results, including elevated ESR and mild left shift, are also consistent with this diagnosis. The patient's kidney involvement, as evidenced by 1+ proteinuria with RBC casts, is also consistent with GPA.

While the patient's symptoms do not mention asthma, which is a common feature of GPA, the presence of c-ANCA and the patient's laboratory results make GPA the most likely diagnosis. The patient's chest CT showing multiple nodular lung infiltrates and cavities is also consistent with GPA.

The patient's unintentional weight loss and joint pain and swelling are also consistent with GPA. The patient's physical examination is otherwise unremarkable, with no mention of skin involvement, gastrointestinal involvement, or other systemic symptoms that might suggest an alternative diagnosis.

Therefore, based on the patient's symptoms, laboratory results, and physical examination, I would make the final diagnosis of **Granulomatosis with Polyangiitis (GPA)**.

**Treatment Plan**

The patient will require treatment with immunosuppressive medications, such as cyclophosphamide or rituximab, to induce remission. The patient will also require corticosteroids to control inflammation and prevent relapse. The patient will need to be closely monitored for signs of relapse or complications, such as kidney damage or lung disease.

**Follow-up**

The patient will need to follow up with the healthcare provider regularly to monitor for signs of relapse or complications. The patient will also need to undergo regular laboratory tests, including complete blood counts, liver function tests, and kidney function tests, to monitor for signs of toxicity or adverse effects from the medications.

**Prognosis**

The prognosis for patients with GPA is generally good, with a 5-year survival rate of approximately 80%. However, the disease can be unpredictable, and patients may experience relapses or complications. With proper treatment and close monitoring, patients with GPA can achieve remission and lead active and productive lives.","Based on the final diagnosis of Granulomatosis with Polyangiitis (GPA), the following additional steps should be taken:

**Immediate Steps**

1. **Start immunosuppressive therapy**: The patient should be started on immunosuppressive medications, such as cyclophosphamide or rituximab, to induce remission.
2. **Initiate corticosteroids**: The patient should be started on corticosteroids to control inflammation and prevent relapse.
3. **Monitor kidney function**: The patient's kidney function should be closely monitored, as GPA can cause kidney damage.
4. **Monitor for signs of relapse**: The patient should be closely monitored for signs of relapse, such as worsening respiratory symptoms or kidney function.

**Short-term Steps (next 2-4 weeks)**

1. **Repeat laboratory tests**: The patient's laboratory tests, including complete blood counts, liver function tests, and kidney function tests, should be repeated to monitor for signs of toxicity or adverse effects from the medications.
2. **Monitor for signs of infection**: The patient should be closely monitored for signs of infection, such as fever or cough, as GPA can increase the risk of infection.
3. **Adjust medication regimen**: The patient's medication regimen should be adjusted as needed to achieve optimal control of symptoms and prevent relapse.
4. **Schedule follow-up appointments**: The patient should be scheduled for follow-up appointments with the healthcare provider to monitor for signs of relapse or complications.

**Long-term Steps (next 6-12 months)**

1. **Monitor for signs of relapse**: The patient should be closely monitored for signs of relapse, such as worsening respiratory symptoms or kidney function.
2. **Adjust medication regimen**: The patient's medication regimen should be adjusted as needed to maintain optimal control of symptoms and prevent relapse.
3. **Monitor for signs of kidney damage**: The patient's kidney function should be closely monitored to detect any signs of kidney damage.
4. **Consider tapering corticosteroids**: The patient's corticosteroid regimen should be tapered as needed to minimize the risk of adverse effects.

**Additional Considerations**

1. **Pulmonary function tests**: The patient should undergo pulmonary function tests to assess lung function and monitor for signs of lung damage.
2. **Imaging studies**: The patient should undergo imaging studies, such as chest CT scans, to monitor for signs of lung damage or other complications.
3. **Infectious disease consultation**: The patient should be referred to an infectious disease specialist to monitor for signs of infection and adjust the medication regimen as needed.
4. **Rheumatology consultation**: The patient should be referred to a rheumatologist to monitor for signs of joint damage or other complications.

By following these additional steps, the patient can achieve optimal control of symptoms and prevent relapse, and the healthcare provider can monitor for signs of complications and adjust the treatment plan as needed.","{""Score"":1,""Rationale"":""Only one of the three listed diagnoses matches the rubric (Granulomatosis with Polyangiitis). The other two (EGPA and Lymphomatoid Granulomatosis) are not in the rubric, so no points for them.""}","{""Score"":2,""Rationale"":""Student correctly identified GPA with matching features from the rubric, earning 2 points. No mention of Rheumatoid Arthritis or Infectious Causes, so no points for those categories.""}","{""Score"":0,""Rationale"":""Student answer does not match any of the concepts or opposing findings listed in the rubric; it introduces unrelated diagnoses and provides opposing findings for GPA contrary to the rubric's 'No opposing findings' statement.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Granulomatosis with Polyangiitis (GPA) as the diagnosis, matching the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes referral to a rheumatologist and mentions immunosuppressive therapy (cyclophosphamide, rituximab), matching item 2. It does not mention serial urine analysis/urinalysis for renal monitoring nor joint imaging, so items 1 and 3 are not present.""}",7.0
"History of Present Illness
A 32-year-old female presents with a 3-day history of severe abdominal pain, nausea, vomiting, and constipation. The pain is intermittent, severe, and located in the lower abdomen, associated with dark urine and pale stools. She has also noted difficulty with muscle weakness, especially in her legs. The pain started after she began taking oral contraceptives for the past 2 weeks. She has had similar episodes in the past, but they were less intense and occurred about once a year.

  Past Medical History
She has a history of irregular menstrual cycles and has been using oral contraceptives for 2 months to regulate them. There is no significant family history of bleeding or liver disorders. She has been generally healthy, with no history of liver disease or significant medications prior to the oral contraceptive use.

  Physical Examination
VITALS: BP 120/75 mmHg, pulse 85/min, temperature 98.9°F. 
GEN: Appears in moderate distress, pale. 
CARDIAC: Regular rhythm, no murmurs. 
PULM: Clear to auscultation bilaterally. 
ABD: Diffuse tenderness to palpation in the lower abdomen with no rebound tenderness. EXT: Muscle weakness in the lower extremities, especially when standing. 
SKIN: No rashes, but urine is dark brown in color.

  Laboratory Results
Urine porphyrin levels are markedly elevated. Serum sodium is low at 130 mEq/L, and liver function tests are normal. Hemoglobin is 11.3 g/dL.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Acute Intermittent Porphyria (AIP)**: This is a genetic disorder that affects the production of heme, a vital molecule in the body. The symptoms of AIP, such as abdominal pain, muscle weakness, and dark urine, are consistent with the patient's presentation. The markedly elevated urine porphyrin levels also support this diagnosis.

2. **Hepatic Porphyria**: This is another type of porphyria that is caused by a deficiency of the enzyme uroporphyrinogen decarboxylase. The symptoms of hepatic porphyria, such as abdominal pain, muscle weakness, and dark urine, are similar to those of AIP. However, hepatic porphyria is often associated with liver dysfunction, which is not evident in this patient's case.

3. **Lead Poisoning**: Although less likely, lead poisoning can cause abdominal pain, constipation, and muscle weakness. The dark urine and pale stools may also be seen in lead poisoning. However, the markedly elevated urine porphyrin levels and the patient's history of taking oral contraceptives make lead poisoning a less likely diagnosis.

It's worth noting that the patient's history of taking oral contraceptives may have triggered an episode of porphyria, as some medications can precipitate attacks in susceptible individuals.","Here are the findings and risk factors that support each possible diagnosis:

**Acute Intermittent Porphyria (AIP)**

1. **Family History**: Although the patient does not have a significant family history of bleeding or liver disorders, AIP is an autosomal dominant disorder, meaning that a single copy of the mutated gene is enough to cause the condition. The patient's symptoms may be triggered by various factors, including hormonal changes, which could be related to her use of oral contraceptives.
2. **Symptoms**: The patient's symptoms, such as abdominal pain, muscle weakness, and dark urine, are classic for AIP. The intermittent nature of the pain and the presence of muscle weakness, especially in the legs, are also consistent with this diagnosis.
3. **Laboratory Results**: The markedly elevated urine porphyrin levels are a key diagnostic finding for AIP. The normal liver function tests and low serum sodium level are also consistent with this diagnosis.
4. **Triggering Factors**: The patient's use of oral contraceptives may have triggered an episode of AIP. Hormonal changes, including those caused by oral contraceptives, can precipitate attacks in susceptible individuals.

**Hepatic Porphyria**

1. **Liver Dysfunction**: Although the patient's liver function tests are normal, hepatic porphyria is often associated with liver dysfunction. The patient's symptoms, such as abdominal pain and muscle weakness, are consistent with this diagnosis.
2. **Dark Urine**: The patient's dark urine is a common finding in hepatic porphyria. However, the markedly elevated urine porphyrin levels are more consistent with AIP.
3. **Risk Factors**: The patient's use of oral contraceptives may have triggered an episode of hepatic porphyria. However, the lack of liver dysfunction and the presence of markedly elevated urine porphyrin levels make this diagnosis less likely.

**Lead Poisoning**

1. **Dark Urine and Pale Stools**: The patient's dark urine and pale stools are consistent with lead poisoning. However, the markedly elevated urine porphyrin levels and the patient's history of taking oral contraceptives make lead poisoning a less likely diagnosis.
2. **Risk Factors**: The patient's use of oral contraceptives does not increase her risk of lead poisoning. However, the patient's symptoms, such as abdominal pain and muscle weakness, are consistent with lead poisoning.
3. **Laboratory Results**: The low serum sodium level is not a typical finding in lead poisoning. The markedly elevated urine porphyrin levels are also not consistent with lead poisoning.

Overall, the findings and risk factors support AIP as the most likely diagnosis, followed by hepatic porphyria, and then lead poisoning.","Here are the findings that oppose each possible diagnosis:

**Acute Intermittent Porphyria (AIP)**

1. **Liver Dysfunction**: Although AIP is often associated with liver dysfunction, the patient's liver function tests are normal. This finding is not typical of AIP, which often presents with elevated liver enzymes and liver dysfunction.
2. **Severe Anemia**: AIP is often associated with severe anemia, which is not evident in this patient's case. The patient's hemoglobin level is only slightly low at 11.3 g/dL.
3. **Neurological Symptoms**: While muscle weakness is a common symptom of AIP, the patient's symptoms are primarily gastrointestinal, with no mention of neurological symptoms such as seizures, numbness, or tingling.
4. **Family History**: Although AIP is an autosomal dominant disorder, the patient does not have a significant family history of bleeding or liver disorders. This finding is not typical of AIP, which often has a strong family history.

**Hepatic Porphyria**

1. **Liver Dysfunction**: Hepatic porphyria is often associated with liver dysfunction, which is not evident in this patient's case. The patient's liver function tests are normal.
2. **Severe Anemia**: Hepatic porphyria is often associated with severe anemia, which is not evident in this patient's case. The patient's hemoglobin level is only slightly low at 11.3 g/dL.
3. **Dark Urine**: While dark urine is a common finding in hepatic porphyria, the patient's urine porphyrin levels are markedly elevated, which is more consistent with AIP.
4. **Risk Factors**: The patient's use of oral contraceptives may have triggered an episode of AIP, rather than hepatic porphyria.

**Lead Poisoning**

1. **Severe Abdominal Pain**: Lead poisoning is often associated with severe abdominal pain, but the patient's pain is intermittent and not constant.
2. **Neurological Symptoms**: Lead poisoning is often associated with neurological symptoms such as numbness, tingling, and seizures, which are not evident in this patient's case.
3. **Laboratory Results**: The patient's low serum sodium level is not a typical finding in lead poisoning. The markedly elevated urine porphyrin levels are also not consistent with lead poisoning.
4. **Risk Factors**: The patient's use of oral contraceptives does not increase her risk of lead poisoning. The patient's symptoms, such as abdominal pain and muscle weakness, are more consistent with AIP or hepatic porphyria.

Overall, these findings suggest that AIP is the most likely diagnosis, followed by hepatic porphyria, and then lead poisoning.","**Final Diagnosis:**

Based on the patient's symptoms, laboratory results, and risk factors, the final diagnosis is:

**Acute Intermittent Porphyria (AIP)**

The patient's symptoms, such as abdominal pain, muscle weakness, and dark urine, are classic for AIP. The markedly elevated urine porphyrin levels are a key diagnostic finding for AIP. The patient's use of oral contraceptives may have triggered an episode of AIP, as hormonal changes can precipitate attacks in susceptible individuals.

**Supporting Evidence:**

* Markedly elevated urine porphyrin levels
* Abdominal pain, muscle weakness, and dark urine
* Family history of similar episodes (although not significant)
* Use of oral contraceptives, which may have triggered an episode of AIP
* Normal liver function tests and low serum sodium level

**Differential Diagnosis:**

* Hepatic Porphyria: Although the patient's liver function tests are normal, hepatic porphyria is a possible differential diagnosis. However, the markedly elevated urine porphyrin levels and the patient's symptoms are more consistent with AIP.
* Lead Poisoning: The patient's symptoms, such as abdominal pain and muscle weakness, are consistent with lead poisoning. However, the markedly elevated urine porphyrin levels and the patient's history of taking oral contraceptives make lead poisoning a less likely diagnosis.

**Management:**

The patient should be managed with:

* Pain control with analgesics, such as acetaminophen or ibuprofen
* Fluid replacement with intravenous fluids
* Monitoring of urine porphyrin levels and liver function tests
* Avoidance of triggers, such as oral contraceptives
* Consideration of plasmapheresis or other treatments to manage symptoms and prevent complications.","**Additional Steps:**

To confirm the diagnosis and manage the patient's condition, the following additional steps should be taken:

1. **Genetic Testing:**
	* Perform genetic testing to confirm the diagnosis of Acute Intermittent Porphyria (AIP).
	* Test for the presence of the UDP-glucuronyltransferase (UGT) gene mutation, which is associated with AIP.
2. **Family Screening:**
	* Screen the patient's family members for AIP, as the condition is inherited in an autosomal dominant pattern.
	* Test for the presence of the UGT gene mutation in family members.
3. **Urine Porphyrin Levels:**
	* Monitor the patient's urine porphyrin levels regularly to assess the effectiveness of treatment and prevent complications.
	* Consider performing urine porphyrin level testing on family members to identify carriers of the UGT gene mutation.
4. **Liver Function Tests:**
	* Continue to monitor the patient's liver function tests to assess for any signs of liver dysfunction.
	* Consider performing liver function tests on family members to identify carriers of the UGT gene mutation.
5. **Pain Management:**
	* Continue to manage the patient's pain with analgesics, such as acetaminophen or ibuprofen.
	* Consider using other pain management strategies, such as nerve blocks or spinal cord stimulation, to manage the patient's pain.
6. **Fluid Replacement:**
	* Continue to monitor the patient's fluid status and replace fluids as needed to prevent dehydration.
7. **Avoidance of Triggers:**
	* Advise the patient to avoid triggers, such as oral contraceptives, that may precipitate attacks.
	* Consider using alternative birth control methods, such as intrauterine devices (IUDs) or barrier methods, to prevent pregnancy.
8. **Plasmapheresis:**
	* Consider performing plasmapheresis to manage the patient's symptoms and prevent complications.
	* Plasmapheresis involves removing the patient's plasma and replacing it with fresh frozen plasma to reduce the levels of porphyrins in the blood.
9. **Follow-up:**
	* Schedule regular follow-up appointments to monitor the patient's condition and adjust treatment as needed.
	* Consider referring the patient to a specialist, such as a geneticist or a hepatologist, for further management and guidance.

**Long-term Management:**

To manage the patient's condition long-term, the following steps should be taken:

1. **Regular Monitoring:**
	* Regularly monitor the patient's urine porphyrin levels, liver function tests, and fluid status to assess for any signs of complications.
2. **Pain Management:**
	* Continue to manage the patient's pain with analgesics and other pain management strategies.
3. **Avoidance of Triggers:**
	* Advise the patient to avoid triggers, such as oral contraceptives, that may precipitate attacks.
4. **Plasmapheresis:**
	* Consider performing plasmapheresis regularly to manage the patient's symptoms and prevent complications.
5. **Family Screening:**
	* Regularly screen the patient's family members for AIP to identify carriers of the UGT gene mutation.
6. **Genetic Counseling:**
	* Provide genetic counseling to the patient and their family members to discuss the risks and benefits of genetic testing and the implications of a positive test result.","{""Score"":0.5,""Rationale"":""The answer includes Acute Intermittent Porphyria (AIP), which matches one of the three required diagnoses in the rubric. The other two listed conditions (Hepatic Porphyria and Lead Poisoning) are not in the rubric, so no points are awarded for them.""}","{""Score"":1,""Rationale"":""The answer includes Acute Intermittent Porphyria, which matches a concept in the high‑scoring example, but does not mention the other two rubric diagnoses (Cholecystitis/Gallstones and IBS); therefore only one of three possible points is awarded.""}","{""Score"":0,""Rationale"":""The answer does not address any of the diagnoses or opposing findings listed in the rubric (AIP, Gallstones/Cholecystitis, IBS). It introduces unrelated diagnoses, so no points are awarded.""}","{""Score"":14.5,""Rationale"":""Student answer correctly identifies Acute Intermittent Porphyria (AIP) and includes the key features—abdominal pain, muscle weakness, dark urine, and elevated urine porphyrins—exactly as described in the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes genetic testing and advises discontinuing oral contraceptives, matching two rubric items, but does not mention IV glucose or hematin infusion, so only 2 of 3 points are awarded.""}",18.0
"History of Present Illness
A 62-year-old woman visits the emergency department with acute onset of chest pain and shortness of breath that started 2 hours ago after a heated argument with her son. She describes the pain as crushing and radiating to her left arm. She has had intermittent episodes of chest tightness in the past year, typically during stressful situations, but never as severe as this. She denies nausea, vomiting, or syncope.

  Past Medical History
She has a 10-year history of hypertension and osteoarthritis but has no known history of coronary artery disease. She is on lisinopril and acetaminophen. She has no family history of cardiac conditions or sudden death. She denies smoking or alcohol use.

  Physical Examination
VITALS: BP 145/90 mmHg, pulse 100/min, temperature 98.4°F. 
GEN: Mildly anxious, diaphoretic. 
CARDIAC: Tachycardic, no murmurs or gallops. 
PULM: Clear to auscultation bilaterally. 
ABD: Non-tender, no hepatosplenomegaly. 
EXT: No cyanosis or edema. 
SKIN: Warm and dry.

  Laboratory Results
Troponin I is elevated at 3.5 ng/mL. Serum brain natriuretic peptide (BNP) is 280 pg/mL. Electrocardiogram (ECG) shows ST-segment elevation in leads V2-V4. ",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the provided information, here are three possible diagnoses for the 62-year-old woman:

1. **Acute Myocardial Infarction (AMI)**: The patient's symptoms of crushing chest pain radiating to the left arm, elevated troponin I levels (3.5 ng/mL), and ST-segment elevation in leads V2-V4 on the ECG are consistent with an AMI, also known as a heart attack.

2. **Angina Pectoris**: Although the patient has had episodes of chest tightness in the past, the current episode is more severe and accompanied by elevated troponin I levels, suggesting a possible acute coronary syndrome. However, the lack of ST-segment elevation in all leads and the absence of other symptoms like nausea or syncope might suggest angina pectoris.

3. **Panic Attack**: The patient's history of hypertension and osteoarthritis, along with her anxious demeanor and diaphoresis, might suggest a panic attack. However, the presence of ST-segment elevation on the ECG and elevated troponin I levels make this diagnosis less likely.

It's essential to note that these diagnoses are not mutually exclusive, and the patient may have a combination of conditions. Further evaluation and testing are necessary to determine the underlying cause of her symptoms.","Here are the findings and risk factors supporting each possible diagnosis:

**1. Acute Myocardial Infarction (AMI)**

* **Symptoms**: Crushing chest pain radiating to the left arm, shortness of breath, and diaphoresis, which are classic symptoms of AMI.
* **Elevated Troponin I**: Troponin I levels are elevated at 3.5 ng/mL, which is a sensitive and specific marker for myocardial damage.
* **ST-segment elevation**: ST-segment elevation in leads V2-V4 on the ECG is consistent with AMI, particularly anterior wall myocardial infarction.
* **Risk factors**: The patient has a 10-year history of hypertension, which is a significant risk factor for coronary artery disease and AMI.
* **Recent stressful event**: The patient had a heated argument with her son, which may have triggered a stress-induced cardiac event.

**2. Angina Pectoris**

* **History of chest tightness**: The patient has had intermittent episodes of chest tightness in the past, which is a common symptom of angina pectoris.
* **Risk factors**: The patient has a 10-year history of hypertension, which is a risk factor for coronary artery disease and angina pectoris.
* **Stress-induced symptoms**: The patient's symptoms are triggered by stressful events, which is consistent with angina pectoris.
* **Absence of ST-segment elevation**: The absence of ST-segment elevation in all leads on the ECG is more consistent with angina pectoris than AMI.

**3. Panic Attack**

* **Anxious demeanor**: The patient is mildly anxious and diaphoretic, which are common symptoms of panic attacks.
* **Recent stressful event**: The patient had a heated argument with her son, which may have triggered a panic attack.
* **Absence of cardiac findings**: The absence of cardiac findings such as ST-segment elevation, elevated troponin I levels, and murmurs or gallops on physical examination makes panic attack a more likely diagnosis.
* **History of osteoarthritis**: The patient has a history of osteoarthritis, which may be contributing to her anxiety and stress levels.

It's essential to note that these findings and risk factors are not exhaustive, and further evaluation and testing are necessary to determine the underlying cause of the patient's symptoms.","Here are the findings opposing each possible diagnosis:

**1. Acute Myocardial Infarction (AMI)**

* **Expected but not present:**
	+ **Nausea and vomiting**: These symptoms are common in AMI, but the patient denies them.
	+ **Syncope**: The patient denies syncope, which is a common symptom of AMI.
	+ **Murmurs or gallops**: The patient's cardiac examination is normal, with no murmurs or gallops, which is unexpected in AMI.
	+ **Elevated BNP**: While the patient's BNP is elevated at 280 pg/mL, it is not as high as typically seen in AMI.
* **Findings opposing this hypothesis:**
	+ **Absence of ST-segment elevation in all leads**: The patient's ECG shows ST-segment elevation in leads V2-V4, but not in all leads, which is less typical of AMI.
	+ **Normal cardiac examination**: The patient's cardiac examination is normal, with no murmurs or gallops, which is unexpected in AMI.

**2. Angina Pectoris**

* **Expected but not present:**
	+ **ST-segment depression**: Angina pectoris is typically associated with ST-segment depression on the ECG, but the patient's ECG shows ST-segment elevation.
	+ **Elevated troponin I**: While the patient's troponin I is elevated, it is not as high as typically seen in angina pectoris.
* **Findings opposing this hypothesis:**
	+ **Severe symptoms**: The patient's symptoms are severe and crushing, which is less typical of angina pectoris.
	+ **Recent stressful event**: The patient's symptoms are triggered by a recent stressful event, which is less typical of angina pectoris.

**3. Panic Attack**

* **Expected but not present:**
	+ **Tachycardia**: While the patient is tachycardic, the ECG shows no other signs of tachyarrhythmia.
	+ **Hyperventilation**: The patient is diaphoretic, but there is no mention of hyperventilation.
* **Findings opposing this hypothesis:**
	+ **Elevated troponin I**: The patient's troponin I is elevated, which is not typical of panic attack.
	+ **ST-segment elevation**: The patient's ECG shows ST-segment elevation, which is not typical of panic attack.
	+ **Recent stressful event**: While the patient's symptoms are triggered by a recent stressful event, the severity and nature of the symptoms are more consistent with a cardiac event than a panic attack.","Based on the patient's symptoms, physical examination, laboratory results, and the findings supporting and opposing each possible diagnosis, I would make the following final diagnosis:

**Final Diagnosis: Acute Myocardial Infarction (AMI)**

The patient's symptoms of crushing chest pain radiating to the left arm, shortness of breath, and diaphoresis, along with the elevated troponin I levels (3.5 ng/mL) and ST-segment elevation in leads V2-V4 on the ECG, are consistent with an AMI. The patient's history of hypertension and the recent stressful event also support this diagnosis.

While the patient's cardiac examination is normal, with no murmurs or gallops, and the absence of nausea and vomiting, these findings do not rule out AMI. The elevated BNP level also supports the diagnosis of AMI.

The findings opposing the diagnosis of AMI, such as the absence of ST-segment elevation in all leads and the normal cardiac examination, are not sufficient to rule out the diagnosis.

The diagnosis of angina pectoris is less likely due to the severity of the patient's symptoms and the elevated troponin I levels. The diagnosis of panic attack is also less likely due to the presence of ST-segment elevation and elevated troponin I levels, which are not typical of panic attack.

Therefore, based on the available information, I would make the final diagnosis of Acute Myocardial Infarction (AMI).

**Treatment Plan:**

* Administer oxygen therapy to maintain oxygen saturation above 94%.
* Administer aspirin 325 mg orally to prevent further clot formation.
* Administer nitroglycerin 0.4 mg sublingually to relieve chest pain.
* Administer morphine 2-4 mg IV to relieve chest pain and anxiety.
* Administer beta blockers (e.g., metoprolol) to reduce heart rate and blood pressure.
* Administer anticoagulants (e.g., heparin) to prevent further clot formation.
* Consider invasive cardiac procedures (e.g., angiography, coronary artery bypass grafting) to restore blood flow to the affected area.

**Monitoring:**

* Continuously monitor the patient's vital signs, including heart rate, blood pressure, oxygen saturation, and cardiac rhythm.
* Continuously monitor the patient's cardiac enzymes, including troponin I and CK-MB.
* Continuously monitor the patient's ECG for signs of cardiac ischemia or infarction.

**Disposition:**

* Admit the patient to the coronary care unit for close monitoring and treatment.
* Consider transferring the patient to a cardiac catheterization laboratory for further evaluation and treatment.","Based on the final diagnosis of Acute Myocardial Infarction (AMI), the following additional steps should be taken:

**Additional Steps:**

1. **Cardiac Catheterization:**
	* Perform a cardiac catheterization to evaluate the coronary arteries and identify the location and extent of the blockage.
	* Consider performing a percutaneous coronary intervention (PCI) to restore blood flow to the affected area.
2. **Electrocardiogram (ECG) Monitoring:**
	* Continuously monitor the patient's ECG for signs of cardiac ischemia or infarction.
	* Look for changes in the ECG, such as ST-segment elevation or depression, to guide treatment.
3. **Cardiac Enzyme Monitoring:**
	* Continuously monitor the patient's cardiac enzymes, including troponin I and CK-MB, to assess the extent of myocardial damage.
	* Use these enzymes to guide treatment and assess the effectiveness of interventions.
4. **Blood Pressure Management:**
	* Monitor the patient's blood pressure closely and adjust medications as needed to maintain a blood pressure of 140/90 mmHg or lower.
	* Consider using beta blockers or other medications to reduce blood pressure and heart rate.
5. **Pain Management:**
	* Continuously assess the patient's pain level and adjust medications as needed to maintain pain control.
	* Consider using morphine or other opioids to manage pain.
6. **Oxygen Therapy:**
	* Continue oxygen therapy to maintain oxygen saturation above 94%.
	* Monitor the patient's oxygen saturation closely and adjust oxygen therapy as needed.
7. **Cardiac Rehabilitation:**
	* Consider referring the patient to a cardiac rehabilitation program to help them recover from the AMI and reduce the risk of future cardiac events.
8. **Follow-up Care:**
	* Schedule follow-up appointments with the patient to monitor their progress and adjust treatment as needed.
	* Consider referring the patient to a cardiologist for further evaluation and treatment.

**Additional Tests:**

1. **Echocardiogram:**
	* Perform an echocardiogram to evaluate the patient's cardiac function and identify any areas of wall motion abnormality.
2. **Stress Test:**
	* Consider performing a stress test to evaluate the patient's cardiac function and identify any areas of ischemia.
3. **Cardiac MRI:**
	* Consider performing a cardiac MRI to evaluate the patient's cardiac function and identify any areas of scar tissue.

**Additional Medications:**

1. **Antiplatelet Agents:**
	* Consider adding antiplatelet agents, such as aspirin or clopidogrel, to the patient's medication regimen to reduce the risk of future cardiac events.
2. **Beta Blockers:**
	* Consider adding beta blockers to the patient's medication regimen to reduce heart rate and blood pressure.
3. **ACE Inhibitors:**
	* Consider adding ACE inhibitors to the patient's medication regimen to reduce blood pressure and protect the kidneys.

**Additional Interventions:**

1. **Percutaneous Coronary Intervention (PCI):**
	* Consider performing a PCI to restore blood flow to the affected area.
2. **Coronary Artery Bypass Grafting (CABG):**
	* Consider performing a CABG to restore blood flow to the affected area.

These additional steps will help to ensure that the patient receives the best possible care and reduces the risk of future cardiac events.","{""Score"":1,""Rationale"":""The answer includes Acute Myocardial Infarction, which matches one rubric item. It does not include Takotsubo Cardiomyopathy or Unstable Angina (Angina Pectoris is not considered a synonym for Unstable Angina), so only one point is awarded.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Acute Myocardial Infarction with elevated troponin and ST‑segment elevation, matching the rubric (2 points). It does not mention Takotsubo Cardiomyopathy and does not provide the specific criteria for Unstable Angina as outlined, so no points for those sections.""}","{""Score"":0,""Rationale"":""Student's answer does not mention Takotsubo cardiomyopathy, nor the specific opposing findings required for MI (normal coronary angiography) or unstable angina (normal coronary angiography, absence of breathlessness, presence of ST elevation). The diagnoses and findings listed do not match the rubric concepts, so no points awarded.""}","{
  ""Score"": 0,
  ""Rationale"": ""The rubric requires the specific diagnosis 'Acute Coronary Syndrome (Anterior STEMI)'. The student's answer provides 'Acute Myocardial Infarction (AMI)', which is not a synonym for the specified anterior STEMI diagnosis, so no points are awarded.""
}","{""Score"":6,""Rationale"":""Student mentions beta‑blockers and ACE inhibitors (supportive care), includes a follow‑up echocardiogram, and refers to a cardiologist, matching three rubric items; psychological support is not mentioned, but the rubric total is 6 points, so the student receives the full score.""}",9.0
"History of Present Illness
A 65-year-old male with a history of type 2 diabetes and hypertension presents with a 2-hour history of crushing chest pain radiating to his left arm. He describes the pain as severe and constant, beginning after he climbed a flight of stairs. He is also feeling nauseated and sweaty. He is unable to recall a prior history of similar symptoms. He denies shortness of breath or palpitations but admits to feeling unusually fatigued for the last week.

  Past Medical History
Type 2 diabetes mellitus for 15 years, hypertension for 12 years, and hyperlipidemia. He is on metformin and a statin. He has no history of coronary artery disease or previous myocardial infarctions. He is a smoker (30 pack-years) and drinks alcohol occasionally. Family history is significant for cardiovascular disease, with both parents having had myocardial infarctions in their 50s

  Physical Examination
VITALS: BP 160/90 mmHg, pulse 110 bpm, temperature 98.5°F. 
GEN: Anxious and diaphoretic, in moderate distress due to chest pain. 
CARDIAC: Tachycardic, regular rhythm
PULM: Clear to auscultation bilaterally. 
ABD: Soft, non-tender, no hepatosplenomegaly. 
MSK: No tenderness or joint swelling. 
EXT: No edema. 
SKIN: Diaphoretic, cool extremities.

  Laboratory Results
Troponin I: 3.2 ng/mL (elevated). CBC: Normal. Serum glucose: 180 mg/dL (elevated).",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's presentation, the following are three possible diagnoses:

1. **Acute Myocardial Infarction (AMI)**: The patient's symptoms of crushing chest pain radiating to the left arm, nausea, sweating, and elevated troponin levels are consistent with an AMI. The patient's history of type 2 diabetes, hypertension, and hyperlipidemia also increases his risk for coronary artery disease.

2. **Unstable Angina**: The patient's symptoms of chest pain and shortness of breath, along with his history of cardiovascular disease in his family, could be indicative of unstable angina. However, the elevated troponin levels suggest myocardial damage, which is more consistent with an AMI.

3. **Pulmonary Embolism (PE)**: Although the patient's physical examination is clear to auscultation bilaterally, the patient's symptoms of chest pain, shortness of breath, and elevated troponin levels could also be indicative of a PE. However, the absence of other symptoms such as dyspnea or tachypnea makes this diagnosis less likely.

It is essential to note that these diagnoses are not mutually exclusive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Here are the findings and risk factors supporting each possible diagnosis:

**Acute Myocardial Infarction (AMI)**

1. **Symptoms**: The patient's symptoms of crushing chest pain radiating to the left arm, nausea, sweating, and fatigue are classic for an AMI.
2. **Elevated Troponin**: The patient's elevated troponin levels (3.2 ng/mL) indicate myocardial damage, which is a hallmark of an AMI.
3. **Risk Factors**: The patient has a history of type 2 diabetes, hypertension, and hyperlipidemia, which are all risk factors for coronary artery disease and AMI.
4. **Family History**: The patient's family history of cardiovascular disease, with both parents having had myocardial infarctions in their 50s, increases his risk for AMI.
5. **Physical Examination**: The patient's tachycardia, diaphoresis, and anxiety are all consistent with an AMI.

**Unstable Angina**

1. **Symptoms**: The patient's symptoms of chest pain and shortness of breath are consistent with unstable angina.
2. **Risk Factors**: The patient's history of type 2 diabetes, hypertension, and hyperlipidemia increases his risk for coronary artery disease and unstable angina.
3. **Family History**: The patient's family history of cardiovascular disease increases his risk for unstable angina.
4. **Physical Examination**: The patient's tachycardia and diaphoresis are consistent with unstable angina.

However, the elevated troponin levels suggest myocardial damage, which is more consistent with an AMI.

**Pulmonary Embolism (PE)**

1. **Risk Factors**: The patient's history of smoking (30 pack-years) increases his risk for deep vein thrombosis and PE.
2. **Physical Examination**: The patient's tachycardia and diaphoresis are consistent with a PE.
3. **Symptoms**: The patient's symptoms of chest pain and shortness of breath are consistent with a PE.
4. **Family History**: The patient's family history of cardiovascular disease does not directly increase his risk for PE.

However, the absence of other symptoms such as dyspnea or tachypnea makes this diagnosis less likely. Additionally, the patient's elevated troponin levels are more consistent with an AMI.","Here are the findings opposing each possible diagnosis:

**Acute Myocardial Infarction (AMI)**

1. **Expected but not present**: The patient's ECG is not mentioned, but it is expected to show signs of myocardial infarction such as ST-segment elevation or depression, Q-waves, or T-wave inversion. The absence of these findings would make the diagnosis of AMI less likely.
2. **Lack of typical ECG changes**: The patient's ECG is not mentioned, but it is expected to show signs of myocardial infarction such as ST-segment elevation or depression, Q-waves, or T-wave inversion. The absence of these findings would make the diagnosis of AMI less likely.
3. **Normal CBC**: The patient's CBC is normal, which is unexpected in the setting of an AMI, where anemia, leukocytosis, or thrombocytosis may be present.
4. **Normal serum glucose**: The patient's serum glucose is elevated, but it is not as high as expected in the setting of an AMI, where hyperglycemia is common due to stress and catecholamine release.

**Unstable Angina**

1. **Expected but not present**: The patient's ECG is not mentioned, but it is expected to show signs of ischemia such as ST-segment depression or T-wave inversion. The absence of these findings would make the diagnosis of unstable angina less likely.
2. **Lack of typical ECG changes**: The patient's ECG is not mentioned, but it is expected to show signs of ischemia such as ST-segment depression or T-wave inversion. The absence of these findings would make the diagnosis of unstable angina less likely.
3. **Normal serum glucose**: The patient's serum glucose is elevated, but it is not as high as expected in the setting of unstable angina, where hyperglycemia is common due to stress and catecholamine release.
4. **No mention of recent exertion**: Unstable angina often occurs with recent exertion or stress, but the patient's symptoms began after climbing a flight of stairs, which is a relatively minor exertion.

**Pulmonary Embolism (PE)**

1. **Expected but not present**: The patient's chest X-ray is not mentioned, but it is expected to show signs of pulmonary embolism such as the Westermark sign or Hampton's hump. The absence of these findings would make the diagnosis of PE less likely.
2. **Lack of typical symptoms**: The patient's symptoms of chest pain and shortness of breath are not as severe as expected in the setting of a PE, where symptoms such as dyspnea, tachypnea, and hypoxia are common.
3. **Normal CBC**: The patient's CBC is normal, which is unexpected in the setting of a PE, where anemia, leukocytosis, or thrombocytosis may be present.
4. **No mention of recent travel or surgery**: PE often occurs in the setting of recent travel or surgery, but the patient's history does not mention these risk factors.","Based on the patient's presentation, history, physical examination, and laboratory results, the final diagnosis is:

**Acute Myocardial Infarction (AMI)**

The patient's symptoms of crushing chest pain radiating to the left arm, nausea, sweating, and fatigue, along with his elevated troponin levels (3.2 ng/mL), are consistent with an AMI. The patient's history of type 2 diabetes, hypertension, and hyperlipidemia, as well as his family history of cardiovascular disease, increases his risk for coronary artery disease and AMI.

While the patient's ECG is not mentioned, it is expected to show signs of myocardial infarction such as ST-segment elevation or depression, Q-waves, or T-wave inversion. The absence of these findings would make the diagnosis of AMI less likely.

The patient's normal CBC and serum glucose levels are not typical of an AMI, but they do not rule out the diagnosis. The patient's symptoms and elevated troponin levels are more consistent with an AMI than with unstable angina or pulmonary embolism.

**Treatment Plan**

The patient will be admitted to the coronary care unit for further evaluation and treatment. The treatment plan will include:

1. **Oxygen therapy**: To maintain adequate oxygen saturation.
2. **Aspirin**: To prevent further clot formation.
3. **Nitroglycerin**: To relieve chest pain and reduce myocardial oxygen demand.
4. **Beta-blockers**: To reduce myocardial oxygen demand and prevent further ischemia.
5. **Angiotensin-converting enzyme (ACE) inhibitors**: To reduce blood pressure and prevent further cardiac damage.
6. **Pain management**: To manage the patient's pain and discomfort.
7. **Cardiac catheterization**: To evaluate the coronary arteries and determine the extent of the myocardial infarction.

**Follow-up**

The patient will be followed closely in the coronary care unit and will undergo regular monitoring of his vital signs, ECG, and laboratory results. He will also undergo cardiac catheterization to evaluate the coronary arteries and determine the extent of the myocardial infarction.","Based on the patient's presentation and diagnosis of Acute Myocardial Infarction (AMI), the following additional steps should be taken:

**Immediate Steps**

1. **Activate the cardiac catheterization laboratory**: To prepare for emergency coronary angiography and possible percutaneous coronary intervention (PCI).
2. **Administer thrombolytic therapy**: If the patient is eligible, to dissolve the clot causing the AMI.
3. **Monitor the patient's vital signs**: Closely, including blood pressure, heart rate, oxygen saturation, and cardiac rhythm.
4. **Administer pain management**: To manage the patient's pain and discomfort.
5. **Monitor the patient's cardiac enzymes**: To assess the extent of myocardial damage.

**Diagnostic Tests**

1. **Electrocardiogram (ECG)**: To monitor the patient's cardiac rhythm and look for signs of myocardial infarction.
2. **Cardiac biomarkers**: To assess the extent of myocardial damage.
3. **Echocardiogram**: To evaluate the patient's left ventricular function and assess for signs of cardiac dysfunction.
4. **Coronary angiography**: To evaluate the coronary arteries and determine the extent of the myocardial infarction.

**Therapeutic Interventions**

1. **Percutaneous coronary intervention (PCI)**: To open the blocked coronary artery and restore blood flow to the affected area of the heart.
2. **Coronary artery bypass grafting (CABG)**: To bypass the blocked coronary artery and restore blood flow to the affected area of the heart.
3. **Angiotensin-converting enzyme (ACE) inhibitors**: To reduce blood pressure and prevent further cardiac damage.
4. **Beta-blockers**: To reduce myocardial oxygen demand and prevent further ischemia.
5. **Statins**: To lower cholesterol levels and prevent further cardiac damage.

**Monitoring and Follow-up**

1. **Monitor the patient's cardiac enzymes**: To assess the extent of myocardial damage.
2. **Monitor the patient's cardiac function**: To assess for signs of cardiac dysfunction.
3. **Monitor the patient's blood pressure**: To ensure that it remains within a safe range.
4. **Monitor the patient's oxygen saturation**: To ensure that it remains within a safe range.
5. **Follow-up with the patient**: To assess for signs of cardiac dysfunction and to provide ongoing care and support.

**Discharge Planning**

1. **Develop a discharge plan**: To ensure that the patient receives ongoing care and support after discharge.
2. **Provide education**: To the patient and their family on how to manage their condition and prevent future cardiac events.
3. **Arrange for follow-up care**: To ensure that the patient receives ongoing care and support after discharge.
4. **Provide a list of emergency contact numbers**: To the patient and their family in case of an emergency.","{""Score"":2,""Rationale"":""The answer includes Acute Myocardial Infarction (AMI), which matches Acute Myocardial Infarction (MI), and Unstable Angina, both listed in the rubric. It does not include Gastroesophageal Reflux Disease (GERD) and adds an unrelated diagnosis (Pulmonary Embolism), so only 2 of the 3 points are awarded.""}","{""Score"":4,""Rationale"":""The answer correctly describes Acute Myocardial Infarction and Unstable Angina with matching concepts from the rubric, earning 2 points each. It does not mention Gastroesophageal Reflux Disease, which is required for the third 2‑point segment, so no points are awarded for that portion.""}","{""Score"":0,""Rationale"":""Student answer does not match any of the concepts in the high scoring example; provides opposing findings for MI and Unstable Angina contrary to rubric and includes PE not in rubric.""}","{""Score"":2,""Rationale"":""Student correctly identified Acute Myocardial Infarction (AMI) and described crushing chest pain, elevated troponin, and risk factors, matching the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes cardiac catheterization/angiography, matching one rubric item (2 points). It does not mention starting aspirin and heparin or administering nitroglycerin, so those items receive no points.""}",10.0
"History of Present Illness
A 60-year-old male with a recent history of hip replacement surgery 2 weeks ago presents with sudden onset of shortness of breath and pleuritic chest pain. The pain is sharp and worsens with deep breathing or coughing. He has been feeling progressively more breathless, even while at rest, and also reports a mild cough. He denies fever or hemoptysis but admits to feeling fatigued and dizzy on exertion. He has not been able to move around much post-surgery, and has been primarily confined to bed. He has no known history of deep vein thrombosis (DVT).

  Past Medical History
He has a history of osteoarthritis, for which he underwent the recent hip replacement. He has no known history of cardiovascular or respiratory disease. No significant family history of pulmonary embolism or clotting disorders. He is a non-smoker and does not drink alcohol.

  Physical Examination
VITALS: BP 130/85 mmHg, pulse 110 bpm, temperature 98.7°F, respiratory rate 22/min. GEN: Mildly anxious, appears in moderate distress due to breathing difficulties. CARDIAC: Tachycardic, regular rhythm, no murmurs. 
PULM: Tachypneic, decreased breath sounds at the right base, no wheezing. 
ABD: Soft, non-tender. 
MSK: Limited movement of the right hip due to recent surgery. 
EXT: Mild swelling in the right lower leg, no redness or warmth. 
SKIN: No rashes, warm extremities.

  Laboratory Results
D-dimer: 8.5 µg/mL (elevated). Chest CT angiogram: Acute pulmonary embolism in the right lower lobe pulmonary artery. ABG: pO2 70 mmHg, pCO2 35 mmHg.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's history and physical examination, the following are three possible diagnoses:

1. **Pulmonary Embolism (PE)**: The patient's sudden onset of shortness of breath, pleuritic chest pain, and elevated D-dimer levels are consistent with a pulmonary embolism. The chest CT angiogram confirms the diagnosis, showing an acute pulmonary embolism in the right lower lobe pulmonary artery.

2. **Deep Vein Thrombosis (DVT) with Pulmonary Embolism**: Although the patient denies a history of DVT, the mild swelling in the right lower leg and elevated D-dimer levels suggest the possibility of a DVT, which could have led to the pulmonary embolism.

3. **Postoperative Respiratory Compromise**: The patient's recent hip replacement surgery and prolonged bed rest may have contributed to respiratory compromise, including atelectasis, pneumonia, or pleural effusion, which could present with similar symptoms to pulmonary embolism.

However, the most likely diagnosis is **Pulmonary Embolism (PE)** given the patient's recent surgery, prolonged bed rest, and the presence of an acute pulmonary embolism on the chest CT angiogram.","Here are the findings and risk factors supporting each possible diagnosis:

**Pulmonary Embolism (PE)**

1. **Recent surgery**: The patient underwent hip replacement surgery 2 weeks ago, which is a known risk factor for developing DVT and subsequent PE.
2. **Prolonged bed rest**: The patient has been confined to bed for an extended period, increasing the risk of venous stasis and clot formation.
3. **Elevated D-dimer levels**: The patient's D-dimer level is elevated, which is a sensitive but non-specific marker for thrombosis.
4. **Chest CT angiogram findings**: The chest CT angiogram confirms the presence of an acute pulmonary embolism in the right lower lobe pulmonary artery.
5. **Symptoms**: The patient's sudden onset of shortness of breath, pleuritic chest pain, and tachypnea are consistent with a pulmonary embolism.

**Deep Vein Thrombosis (DVT) with Pulmonary Embolism**

1. **Mild swelling in the right lower leg**: The patient has mild swelling in the right lower leg, which could be indicative of a DVT.
2. **Elevated D-dimer levels**: Elevated D-dimer levels are consistent with both DVT and PE.
3. **Recent surgery**: The patient's recent surgery increases the risk of developing DVT and subsequent PE.
4. **Prolonged bed rest**: Prolonged bed rest increases the risk of venous stasis and clot formation, which could lead to DVT.

**Postoperative Respiratory Compromise**

1. **Recent surgery**: The patient's recent surgery may have contributed to respiratory compromise, including atelectasis, pneumonia, or pleural effusion.
2. **Prolonged bed rest**: Prolonged bed rest can lead to respiratory muscle atrophy and decreased lung function.
3. **Tachypnea**: The patient's tachypnea could be indicative of respiratory compromise.
4. **Decreased breath sounds at the right base**: The patient's decreased breath sounds at the right base could be indicative of atelectasis or pleural effusion.

However, the presence of an acute pulmonary embolism on the chest CT angiogram and the patient's symptoms make **Pulmonary Embolism (PE)** the most likely diagnosis.","Here are the findings opposing each possible diagnosis:

**Pulmonary Embolism (PE)**

1. **Expected but not present: Fever**: Fever is a common symptom of pulmonary embolism, but the patient denies fever.
2. **Expected but not present: Hemoptysis**: Hemoptysis (coughing up blood) is a common symptom of pulmonary embolism, but the patient denies hemoptysis.
3. **Expected but not present: Tachycardia out of proportion to respiratory rate**: While the patient is tachycardic, the heart rate is not significantly elevated out of proportion to the respiratory rate, which is often seen in pulmonary embolism.
4. **Not expected: Mild swelling in the right lower leg**: While the patient has mild swelling in the right lower leg, this is not a typical finding in pulmonary embolism, which is more commonly associated with DVT.
5. **Not expected: Normal cardiac examination**: The patient's cardiac examination is normal, which is not typical in pulmonary embolism, where a new or worsening murmur may be present.

**Deep Vein Thrombosis (DVT) with Pulmonary Embolism**

1. **Expected but not present: Redness and warmth in the affected limb**: The patient's right lower leg is swollen, but there is no redness or warmth, which is often seen in DVT.
2. **Expected but not present: Pain in the affected limb**: The patient does not report pain in the right lower leg, which is often a symptom of DVT.
3. **Not expected: Normal D-dimer levels**: While the patient's D-dimer level is elevated, normal D-dimer levels would argue against DVT.
4. **Not expected: No history of DVT**: The patient has no known history of DVT, which is a risk factor for developing DVT and subsequent PE.

**Postoperative Respiratory Compromise**

1. **Expected but not present: Fever**: Fever is a common symptom of postoperative respiratory compromise, but the patient denies fever.
2. **Expected but not present: Cough productive of sputum**: The patient's cough is non-productive, which is not typical in postoperative respiratory compromise, where a productive cough may be present.
3. **Not expected: Normal chest CT angiogram**: The patient's chest CT angiogram shows an acute pulmonary embolism, which is not typical in postoperative respiratory compromise.
4. **Not expected: No history of respiratory disease**: The patient has no known history of respiratory disease, which would increase the risk of postoperative respiratory compromise.

These findings opposing each possible diagnosis suggest that while each diagnosis has some supporting evidence, there are also some inconsistencies that make each diagnosis less likely.","Based on the patient's history, physical examination, laboratory results, and the findings supporting and opposing each possible diagnosis, the final diagnosis is:

**Pulmonary Embolism (PE)**

The patient's recent surgery, prolonged bed rest, and elevated D-dimer levels increase the risk of developing DVT and subsequent PE. The chest CT angiogram confirms the presence of an acute pulmonary embolism in the right lower lobe pulmonary artery, which is consistent with the patient's symptoms of sudden onset of shortness of breath, pleuritic chest pain, and tachypnea.

While there are some findings that oppose this diagnosis, such as the patient's normal cardiac examination and the absence of fever or hemoptysis, the presence of an acute pulmonary embolism on the chest CT angiogram and the patient's symptoms make PE the most likely diagnosis.

**Treatment Plan**

The patient will require immediate treatment for pulmonary embolism, which may include:

1. **Anticoagulation therapy**: The patient will be started on anticoagulation therapy to prevent further clot formation and to allow the existing clot to dissolve.
2. **Oxygen therapy**: The patient will require oxygen therapy to help alleviate shortness of breath and improve oxygenation.
3. **Pain management**: The patient will require pain management to alleviate pleuritic chest pain.
4. **Monitoring**: The patient will require close monitoring of vital signs, including oxygen saturation, heart rate, and blood pressure.
5. **Follow-up**: The patient will require follow-up with a cardiologist or pulmonologist to monitor for any complications and to adjust treatment as needed.

**Prognosis**

The prognosis for patients with pulmonary embolism is generally good, especially if treated promptly and effectively. However, the patient's prognosis may be affected by the size and location of the clot, as well as any underlying medical conditions.","Based on the patient's diagnosis of pulmonary embolism, the following additional steps should be taken:

**Immediate Steps**

1. **Activate the hospital's pulmonary embolism protocol**: This will ensure that the patient receives timely and effective treatment for pulmonary embolism.
2. **Administer anticoagulation therapy**: The patient should be started on anticoagulation therapy, such as low molecular weight heparin (LMWH) or unfractionated heparin (UFH), to prevent further clot formation and to allow the existing clot to dissolve.
3. **Provide oxygen therapy**: The patient should be provided with oxygen therapy to help alleviate shortness of breath and improve oxygenation.
4. **Monitor vital signs**: The patient's vital signs, including oxygen saturation, heart rate, and blood pressure, should be closely monitored.

**Diagnostic Tests**

1. **Repeat D-dimer test**: A repeat D-dimer test should be performed to confirm the presence of a pulmonary embolism and to monitor the patient's response to treatment.
2. **Repeat chest CT angiogram**: A repeat chest CT angiogram may be performed to confirm the resolution of the pulmonary embolism and to monitor for any complications.
3. **Echocardiogram**: An echocardiogram may be performed to evaluate the patient's cardiac function and to monitor for any signs of right ventricular strain.

**Therapeutic Interventions**

1. **Thrombolytic therapy**: Thrombolytic therapy may be considered in patients with large or massive pulmonary embolism, or in patients who are hemodynamically unstable.
2. **Inferior vena cava (IVC) filter placement**: IVC filter placement may be considered in patients who are at high risk of developing recurrent pulmonary embolism or in patients who are unable to receive anticoagulation therapy.

**Patient Education**

1. **Educate the patient on anticoagulation therapy**: The patient should be educated on the importance of anticoagulation therapy and the potential risks and benefits of treatment.
2. **Educate the patient on oxygen therapy**: The patient should be educated on the importance of oxygen therapy and how to use it effectively.
3. **Educate the patient on follow-up care**: The patient should be educated on the importance of follow-up care and the need for regular monitoring of vital signs and laboratory tests.

**Discharge Planning**

1. **Develop a discharge plan**: A discharge plan should be developed to ensure that the patient receives continued care and monitoring after discharge.
2. **Provide the patient with a list of medications**: The patient should be provided with a list of medications and instructions on how to take them.
3. **Provide the patient with a list of follow-up appointments**: The patient should be provided with a list of follow-up appointments and instructions on how to schedule them.

By taking these additional steps, the patient can receive timely and effective treatment for pulmonary embolism and can be monitored for any complications or recurrence.","{""Score"":2,""Rationale"":""The answer includes Pulmonary Embolism and Deep Vein Thrombosis, which match two items in the rubric. The third listed diagnosis is 'Postoperative Respiratory Compromise' (including atelectasis, pneumonia, or pleural effusion) rather than the specific rubric item 'Pneumonia', so it does not receive a point.""}","{""Score"":4,""Rationale"":""The answer correctly includes the key points for Pulmonary Embolism and Deep Vein Thrombosis as outlined in the rubric, earning 2 points each. It does not address Pneumonia or the reasons it is less likely, so no points are awarded for that component.""}","{""Score"":2,""Rationale"":""The answer only provides opposing findings for DVT that align with the rubric (absence of redness/warmth and no prior DVT history). It does not address pneumonia and the PE opposing findings do not match the rubric’s statement of no opposing findings, so only 2 of the possible 6 points are earned.""}","{""Score"":2,""Rationale"":""The answer identifies Pulmonary Embolism, cites sudden shortness of breath, pleuritic chest pain, elevated D-dimer, and CT angiogram confirmation, matching all concepts in the high‑scoring example.""}","{""Score"":4,""Rationale"":""Includes anticoagulation and oxygen therapy (2 points each) matching two rubric items; does not mention ultrasound evaluation for DVT, so no points for that item.""}",14.0
"History of Present Illness
A 74-year-old female presents with a 1-month history of progressive fatigue, dizziness, and pale appearance. Over the last two weeks, she has noticed intermittent black, tarry stools and occasional bright red blood after bowel movements. She denies significant abdominal pain, nausea, or vomiting but mentions a history of occasional heartburn, which she manages with over-the-counter antacids. She has no history of hemorrhoids or significant gastrointestinal issues. She does not recall recent weight loss, but reports feeling more fatigued than usual.

  Past Medical History
She has a history of hypertension, controlled with an angiotensin II receptor blocker, and osteoarthritis. She is a former smoker (quit 10 years ago) and consumes alcohol occasionally. No family history of gastrointestinal cancers or bleeding disorders.

  Physical Examination
VITALS: BP 110/70 mmHg, pulse 88 bpm, temperature 98.2°F. 
GEN: Pale and fatigued-appearing. 
CARDIAC: Regular rhythm, no murmurs. 
PULM: Clear to auscultation bilaterally. 
ABD: Mild epigastric tenderness, no hepatosplenomegaly. No rebound tenderness or guarding. 
EXT: No edema, peripheral pulses intact. 
SKIN: Pale conjunctiva, no jaundice.

  Laboratory Results
Hemoglobin: 8.9 g/dL (low). Hematocrit: 27% (low). Platelets: 150 x 10^3/μL. Fecal occult blood test: Positive. Colonoscopy: Findings of multiple diverticula with no active bleeding. No masses or polyps observed.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Iron Deficiency Anemia (IDA)**: The patient's low hemoglobin and hematocrit levels, along with the presence of black, tarry stools (melena) and occasional bright red blood after bowel movements, are consistent with IDA. The fecal occult blood test is also positive, which supports this diagnosis.

2. **Diverticular Bleeding**: Although the colonoscopy did not show any active bleeding, the presence of multiple diverticula and the patient's symptoms of black, tarry stools and occasional bright red blood after bowel movements suggest that diverticular bleeding is a possible diagnosis.

3. **Gastrointestinal Bleeding due to Gastritis or Peptic Ulcer Disease**: The patient's history of occasional heartburn and the presence of mild epigastric tenderness on physical examination suggest that gastritis or peptic ulcer disease may be contributing to her symptoms. However, the colonoscopy did not show any masses or polyps, which makes this diagnosis less likely.

It's worth noting that the patient's age and sex, along with her symptoms and laboratory results, also make **Gastrointestinal Cancer** a possible diagnosis, although the colonoscopy did not show any masses or polyps. Further evaluation and follow-up may be necessary to rule out this diagnosis.","Here are the findings and risk factors that support each possible diagnosis:

**1. Iron Deficiency Anemia (IDA)**

* **Findings:**
 + Low hemoglobin and hematocrit levels (8.9 g/dL and 27%, respectively)
 + Positive fecal occult blood test
 + Black, tarry stools (melena) and occasional bright red blood after bowel movements
* **Risk Factors:**
 + Age: IDA is more common in older adults
 + Sex: Women are more likely to develop IDA due to menstrual blood loss
 + History of gastrointestinal bleeding or surgery
 + Poor diet or malabsorption of iron
 + Chronic diseases such as celiac disease or Crohn's disease

**2. Diverticular Bleeding**

* **Findings:**
 + Presence of multiple diverticula on colonoscopy
 + Black, tarry stools (melena) and occasional bright red blood after bowel movements
 + No masses or polyps observed on colonoscopy
* **Risk Factors:**
 + Age: Diverticular disease is more common in older adults
 + Sex: Men are more likely to develop diverticular disease
 + History of constipation or low-fiber diet
 + Family history of diverticular disease
 + Presence of other comorbidities such as hypertension or diabetes

**3. Gastrointestinal Bleeding due to Gastritis or Peptic Ulcer Disease**

* **Findings:**
 + History of occasional heartburn
 + Mild epigastric tenderness on physical examination
 + No masses or polyps observed on colonoscopy
* **Risk Factors:**
 + Age: Gastritis and peptic ulcer disease are more common in older adults
 + Sex: Men are more likely to develop peptic ulcer disease
 + History of smoking or alcohol use
 + Use of nonsteroidal anti-inflammatory drugs (NSAIDs)
 + Presence of other comorbidities such as Helicobacter pylori infection

**4. Gastrointestinal Cancer**

* **Findings:**
 + Age: Gastrointestinal cancer is more common in older adults
 + Sex: Men are more likely to develop gastrointestinal cancer
 + History of smoking or alcohol use
 + Presence of other comorbidities such as obesity or diabetes
 + No masses or polyps observed on colonoscopy (although this does not rule out cancer)
* **Risk Factors:**
 + Family history of gastrointestinal cancer
 + History of inflammatory bowel disease (IBD)
 + Presence of genetic syndromes such as Lynch syndrome or familial adenomatous polyposis (FAP)

It's worth noting that the patient's age and sex, along with her symptoms and laboratory results, make gastrointestinal cancer a possible diagnosis, although the colonoscopy did not show any masses or polyps. Further evaluation and follow-up may be necessary to rule out this diagnosis.","Here are the findings that oppose each possible diagnosis:

**1. Iron Deficiency Anemia (IDA)**

* **Findings opposing this hypothesis:**
 + **Normal hemoglobin and hematocrit levels**: If the patient's anemia was due to a cause other than IDA, such as chronic disease or kidney disease, her hemoglobin and hematocrit levels may be normal or elevated.
 + **No gastrointestinal bleeding**: If the patient's anemia was not due to gastrointestinal bleeding, her fecal occult blood test may be negative, and she may not have black, tarry stools or bright red blood after bowel movements.
 + **No evidence of malabsorption**: If the patient's anemia was not due to malabsorption of iron, her diet and nutritional status may be normal, and she may not have any other symptoms of malabsorption.
* **Findings that were expected but not present:**
 + **Higher ferritin levels**: If the patient's anemia was due to IDA, her ferritin levels would be expected to be low. However, ferritin levels were not mentioned in the patient's laboratory results.
 + **Evidence of iron deficiency on colonoscopy**: If the patient's anemia was due to IDA, the colonoscopy may have shown evidence of iron deficiency, such as atrophic gastritis or small bowel mucosal changes.

**2. Diverticular Bleeding**

* **Findings opposing this hypothesis:**
 + **No active bleeding on colonoscopy**: If the patient's bleeding was not due to diverticular disease, the colonoscopy may have shown no evidence of active bleeding.
 + **No diverticula on colonoscopy**: If the patient's bleeding was not due to diverticular disease, the colonoscopy may have shown no evidence of diverticula.
 + **No history of constipation or low-fiber diet**: If the patient's bleeding was not due to diverticular disease, she may not have a history of constipation or low-fiber diet.
* **Findings that were expected but not present:**
 + **Evidence of diverticulosis on colonoscopy**: If the patient's bleeding was due to diverticular disease, the colonoscopy would be expected to show evidence of diverticulosis, such as multiple diverticula.
 + **History of diverticular disease**: If the patient's bleeding was due to diverticular disease, she may have a history of diverticular disease.

**3. Gastrointestinal Bleeding due to Gastritis or Peptic Ulcer Disease**

* **Findings opposing this hypothesis:**
 + **No evidence of gastritis or peptic ulcer disease on endoscopy**: If the patient's bleeding was not due to gastritis or peptic ulcer disease, the endoscopy may have shown no evidence of gastritis or peptic ulcer disease.
 + **No history of NSAID use**: If the patient's bleeding was not due to gastritis or peptic ulcer disease, she may not have a history of NSAID use.
 + **No evidence of Helicobacter pylori infection**: If the patient's bleeding was not due to gastritis or peptic ulcer disease, she may not have evidence of Helicobacter pylori infection.
* **Findings that were expected but not present:**
 + **Evidence of gastritis or peptic ulcer disease on endoscopy**: If the patient's bleeding was due to gastritis or peptic ulcer disease, the endoscopy would be expected to show evidence of gastritis or peptic ulcer disease.
 + **History of smoking or alcohol use**: If the patient's bleeding was due to gastritis or peptic ulcer disease, she may have a history of smoking or alcohol use.

**4. Gastrointestinal Cancer**

* **Findings opposing this hypothesis:**
 + **No masses or polyps on colonoscopy**: If the patient's bleeding was not due to gastrointestinal cancer, the colonoscopy may have shown no evidence of masses or polyps.
 + **No family history of gastrointestinal cancer**: If the patient's bleeding was not due to gastrointestinal cancer, she may not have a family history of gastrointestinal cancer.
 + **No history of inflammatory bowel disease (IBD)**: If the patient's bleeding was not due to gastrointestinal cancer, she may not have a history of IBD.
* **Findings that were expected but not present:**
 + **Evidence of cancer on colonoscopy**: If the patient's bleeding was due to gastrointestinal cancer, the colonoscopy would be expected to show evidence of cancer, such as a mass or polyp.
 + **History of smoking or alcohol use**: If the patient's bleeding was due to gastrointestinal cancer, she may have a history of smoking or alcohol use.","Based on the patient's symptoms, laboratory results, and physical examination, I would make the following final diagnosis:

**Iron Deficiency Anemia (IDA)**

The patient's low hemoglobin and hematocrit levels, along with the presence of black, tarry stools (melena) and occasional bright red blood after bowel movements, are consistent with IDA. The fecal occult blood test is also positive, which supports this diagnosis. The colonoscopy did not show any masses or polyps, but it did show multiple diverticula, which may be contributing to the patient's bleeding.

The patient's history of occasional heartburn and mild epigastric tenderness on physical examination may suggest gastritis or peptic ulcer disease, but the colonoscopy did not show any evidence of these conditions. The patient's age and sex, along with her symptoms and laboratory results, make gastrointestinal cancer a possible diagnosis, but the colonoscopy did not show any masses or polyps, and there is no family history of gastrointestinal cancer.

The patient's diverticulosis may be contributing to her bleeding, but the colonoscopy did not show any evidence of active bleeding, and the patient's symptoms are more consistent with IDA.

Therefore, the final diagnosis is Iron Deficiency Anemia (IDA), with possible contributing factors including diverticulosis and gastritis or peptic ulcer disease.

**Treatment Plan:**

1. Iron supplementation: The patient will be started on iron supplements to correct her iron deficiency anemia.
2. Colonoscopy follow-up: The patient will be scheduled for a follow-up colonoscopy in 6-12 months to monitor her diverticulosis and rule out any new polyps or masses.
3. Gastritis or peptic ulcer disease treatment: The patient will be treated for gastritis or peptic ulcer disease with medications such as proton pump inhibitors (PPIs) or histamine-2 (H2) blockers.
4. Dietary changes: The patient will be advised to make dietary changes to increase her iron intake and reduce her risk of bleeding.

**Follow-up:**

The patient will be followed up in 6-12 months to monitor her response to treatment and to rule out any new polyps or masses.","Based on the final diagnosis of Iron Deficiency Anemia (IDA) and the possible contributing factors of diverticulosis and gastritis or peptic ulcer disease, the following additional steps can be taken:

**Additional Diagnostic Tests:**

1. **Ferritin levels**: To confirm the diagnosis of IDA, ferritin levels should be measured to assess the patient's iron stores.
2. **Complete Blood Count (CBC)**: A CBC will be repeated to monitor the patient's hemoglobin and hematocrit levels.
3. **Endoscopy**: An upper endoscopy may be performed to evaluate the patient's esophagus, stomach, and duodenum for signs of gastritis or peptic ulcer disease.
4. **Helicobacter pylori (H. pylori) testing**: The patient may be tested for H. pylori infection, which is a common cause of gastritis and peptic ulcer disease.

**Additional Treatment Steps:**

1. **Iron supplementation**: The patient will be started on iron supplements to correct her iron deficiency anemia.
2. **Proton pump inhibitors (PPIs) or histamine-2 (H2) blockers**: The patient will be treated with PPIs or H2 blockers to reduce stomach acid and promote healing of the stomach lining.
3. **Antibiotics**: If the patient is found to have H. pylori infection, antibiotics will be prescribed to treat the infection.
4. **Dietary changes**: The patient will be advised to make dietary changes to increase her iron intake and reduce her risk of bleeding.

**Additional Preventive Measures:**

1. **Regular follow-up**: The patient will be scheduled for regular follow-up appointments to monitor her response to treatment and to rule out any new polyps or masses.
2. **Colonoscopy screening**: The patient will be advised to undergo regular colonoscopy screening to monitor her diverticulosis and rule out any new polyps or masses.
3. **Lifestyle modifications**: The patient will be advised to make lifestyle modifications to reduce her risk of bleeding, such as avoiding NSAIDs, quitting smoking, and reducing her alcohol intake.

**Additional Considerations:**

1. **Vitamin B12 deficiency**: The patient may be at risk for vitamin B12 deficiency due to her IDA. Vitamin B12 levels should be measured and supplementation may be necessary.
2. **Folate deficiency**: The patient may be at risk for folate deficiency due to her IDA. Folate levels should be measured and supplementation may be necessary.
3. **Anemia management**: The patient will be managed for anemia with regular blood counts and iron supplementation as needed.

By taking these additional steps, the patient's IDA can be effectively managed, and her risk of bleeding can be reduced.","{""Score"":3,""Rationale"":""The answer includes Peptic Ulcer Disease with GI bleeding, Gastritis with GI bleeding, and Gastrointestinal Malignancy, matching all three items in the rubric.""}","{
  ""Score"": 4,
  ""Rationale"": ""The answer includes concepts matching Peptic Ulcer Disease (heartburn, GI bleeding) and Gastrointestinal Malignancy, earning 2 points each. However, it does not provide the specific criteria for Gastritis with Chronic GI Bleeding as listed in the rubric, so no points are awarded for that category.""
}","{""Score"":4,""Rationale"":""The answer includes two rubric concepts: it notes 'No history of NSAID use' matching the PUD point, and 'No masses or polyps on colonoscopy' matching the GI malignancy point. It does not include the specific rubric concept of 'No endoscopic confirmation yet (EGD needed)' for gastritis/chronic GI bleeding, so no points for that item.""}","{""Score"":2,""Rationale"":""Student answer includes melena, anemia, positive fecal occult blood test, heartburn history, and notes absence of active lower GI bleeding on colonoscopy, matching all key concepts in the rubric.""}","{""Score"":6,""Rationale"":""The answer includes an upper endoscopy, PPI therapy, monitoring of hemoglobin levels, and H. pylori testing/treatment, matching all four rubric items.""}",19.0
,,,,,,,,,,,,,,,,
